

Edgar Filing: ASTRALIS LTD - Form 10KSB

ASTRALIS LTD
Form 10KSB
April 21, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-KSB

(Mark One)

ANNUAL REPORT UNDER SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the Fiscal Year Ended December 31, 2005

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ___
Commission File Number: 000-30997

ASTRALIS LTD.
(Name of Small Business Issuer in its Charter)

Delaware

84-1508866

(State or other jurisdiction
of incorporation or organization)

(I.R.S. Employer Identification No.)

75 Passaic Avenue, Fairfield, New Jersey

07004

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (973) 227-7168

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Name of Each Exchange
on Which Registered

None.

None.

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, par value \$.0001 per share

(Title of Class)

Check whether the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes No

Check whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 ("Exchange Act") during the past 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days: Yes No

Edgar Filing: ASTRALIS LTD - Form 10KSB

1

Check mark if no disclosure of delinquent filers pursuant to Item 405 of Regulations S-B is not contained in this form, and no disclosure will be contained, to the best of registrant's knowledge, in a definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB. |_ |

Indicate by check mark whether the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. |_ |

Issuer's revenue for the year ended December 31, 2005: \$0

As of March 31, 2006, the aggregate market value of the voting and nonvoting common stock held by nonaffiliates of the registrant was approximately \$3,457,486.

As of March 31, 2006, there were 91,454,873 shares of the issuer's common stock outstanding.

2

PART I

Item 1. Description of Business

General

Astralis, Ltd. ("Astralis", "we", "us", "our", or the "Company") is a development stage biotechnology company engaged primarily in the research and development of treatments for immune system disorders and skin diseases, such as psoriasis and psoriatic and rheumatoid arthritis. The Company's initial product candidate, Psoraxine(R), is a protein extract used for the treatment of the skin disease psoriasis.

Currently, the Company is engaged in the following activities to further its development efforts of its initial product candidate:

- o Ongoing research and development of Psoraxine(R);
- o Recommencing clinical trials to obtain the approval of the United States Food and Drug Administration for the marketing of Psoraxine(R); and
- o Developing technology underlying Psoraxine(R) for the treatment of indications other than psoriasis, such as arthritis, eczema, seborrheic dermatitis and leishmaniasis.

The Company was originally incorporated under the laws of the State of Colorado in 1999 under the name Hercules Development Group, Inc. We subsequently changed our name to Astralis Pharmaceuticals Ltd. and, in November 2001, reincorporated under the laws of the State of Delaware under our present name. Our main office is located at 75 Passaic Avenue, Fairfield, New Jersey 07004.

Recent Developments

Blue Cedar March 2006 Private Placement

On March 31, 2006, the Company closed a private placement of securities

Edgar Filing: ASTRALIS LTD - Form 10KSB

from which it received proceeds of \$250,000. In connection with this private placement, the Company issued to Blue Cedar Limited ("Blue Cedar"), an accredited investor and currently a stockholder of the Company, (i) a convertible promissory note in the principal amount of \$250,000, convertible into shares of the Company's common stock at \$0.09 per share, and (ii) a warrant to purchase 2,777,778 shares of common stock. Lipworth Capital Limited acted as the placement agent in connection with the private placement. The securities offered and sold in this private placement were sold in reliance on an exemption from the registration requirements under Regulation D of the Securities Act of 1933, as amended (the "Securities Act").

Departure of Directors and Principal Officer

On December 11, 2005, Steven Fulda, a member of the Board of Directors and Audit Committee of the Company, announced his resignation from the Board and Audit Committee, effective December 30, 2005. Mr. Fulda's announcement did not reference a disagreement with the Company on any matter relating to the Company's operations. In addition, on April 19, 2006 Fabien Pictet announced that he will be resigning as a member of the Board of Directors of the Company. Mr. Pictet has not yet announced an effective date of his resignation, nor did his announcement reference a disagreement with the Company on any matter relating to the Company's operations.

On January 25, 2006, James Sharpe resigned as a member of the Board of Directors, Chief Executive Officer and President of the Company, pursuant to a Separation Agreement and General Release, by and between the Company and Mr. Sharpe ("Separation Agreement"). Mr. Sharpe, whose resignation was effective as of December 31, 2005, did not resign due to a disagreement with the Company on any matter relating to the Company's operations. Michael Garone, the Company's Chief Financial Officer, currently is serving as the Company's interim President until the Company's Board of Directors elects a new Chief Executive Officer and President to replace Mr. Sharpe.

3

Limited Working Capital

As of April 15, 2006 we have \$277,705 in available cash and accounts payable of \$65,067. Based on our current plans, we believe the Company has sufficient funds to meet our operating expenses and capital requirements only through approximately May 2006. We will need to raise additional funds to continue our operations following that period. Furthermore, substantial additional funds will be needed in order to fund our continued efforts to obtain FDA approval of Psoraxine(R), especially given the failure of our Phase II study to meet its primary endpoint.

Psoriasis

Psoriasis is a chronic inflammatory skin disorder of currently unknown origins that generally lasts a lifetime and for which there is presently no known cure. Researchers believe that psoriasis may be caused by the immune system sending faulty signals that affect the growth cycle of skin cells. As a result, skin cells accumulate on the surface of the body faster than normal. In people without psoriasis, skin cells mature and are shed approximately every 28 days. In psoriatic skin, the skin cells mature over a period of approximately three to six days.

The symptoms of psoriasis include scaly skin and inflammation occurring on a cyclical basis, with periods of remission and relapse. There are five types of

Edgar Filing: ASTRALIS LTD - Form 10KSB

psoriasis. The most common form, appearing in approximately 80% of individuals suffering from the disease, is plaque psoriasis. The other forms are guttate, inverse, erythrodermic and pustular psoriasis. Psoriasis typically does not prevent individuals with the condition from functioning normally. However, the pain, discomfort and emotional effects may be extensive.

Market Opportunity

According to the National Psoriasis Foundation, psoriasis affects approximately 2.1% of the United States population, or more than 4.5 million people in the United States. Psoriasis also affects approximately 1% to 3% of the world's population. Approximately 150,000 to 260,000 new cases of psoriasis are diagnosed each year. In addition, each year approximately 350 people in the United States die due to complications caused by psoriasis. Primarily, such complications occur in relation to severe, extensive forms of psoriasis such as erythrodermic or pustular psoriasis, where large areas of skin are shed. Because the skin plays an important role in regulating body temperature and serving as a barrier to infection, when a person's skin is severely compromised, secondary infections may occur. These serious forms of psoriasis may also cause complicating factors, such as fluid loss and strain on the circulatory system.

The National Psoriasis Foundation also indicates that between 10% and 30% of people who have psoriasis will also develop psoriatic arthritis, which is similar to rheumatoid arthritis, but generally milder. Psoriatic arthritis causes inflammation and stiffness in the soft tissue around joints, and frequently affects the fingers and toes. Psoriatic arthritis may also affect other areas of the body such as the wrists, neck, lower back, knees and ankles.

Psoriasis is a chronic illness that, in many cases, requires continuous treatment. Patients with psoriasis often pay for costly medications and face ongoing visits with physicians. Severe cases may require periods of hospitalization. The National Psoriasis Foundation estimates that the costs of treating psoriasis may exceed \$3.0 billion annually.

4

Psoraxine (R)

Psoraxine(R) was developed by Dr. Jose Antonio O'Daly, our Chairman of the Board and Chief Scientific Officer. In 1991, Dr. O'Daly was conducting trials for a vaccine for leishmaniasis in Caracas, Venezuela. One patient involved in the leishmaniasis vaccine trials, who also suffered from psoriasis for 12 years, experienced complete remission of psoriasis after receiving the vaccine. As a result of this discovery, Dr. O'Daly focused his efforts on developing a product for the treatment of psoriasis. From 1992 through 2001, Dr. O'Daly developed Psoraxine(R), a purified version of the original product that is an immunotherapeutic agent presented in liquid form and packed in 0.5 milligram ampules for intra-muscular injection. Dr. O'Daly tested the original product that was a precursor of Psoraxine(R) in approximately 2,900 patients in several clinical trials in Venezuela. The results from the studies provided evidence of remission of psoriasis lesions as a result of treatment with the product. In addition, individuals in the studies did not present severe side effects as a result of treatment. In one clinical study, of the 2,770 patients, 648, or 28%, experienced complete remission of psoriasis. In addition, almost half of the patients experienced psoriasis reduction of between 70% to 99% as measured by the Psoriasis Area and Severity Index ("PASI"). Additional studies yielded average PASI reductions of between 73% and 92%.

Dr. O'Daly licensed Psoraxine(R) to us in 2001 and moved to the United States in 2002. We made capital investments to our research and development

Edgar Filing: ASTRALIS LTD - Form 10KSB

facility of approximately \$500,000 in 2002 and we filed an Investigational New Drug application with the FDA for Psoraxine(R) in March 2003. On August 4, 2003 the FDA allowed us to commence our Phase I clinical trials for Psoraxine(R).

The purpose of Phase I studies is to test the safety of a drug. We have completed our Phase I studies, which involved the administration by intramuscular injection of a single dose of 50, 150 or 300 micrograms of Psoraxine(R) or a placebo in a controlled setting to groups of psoriatic patients. Our Phase I results indicate that Psoraxine(R) is safe and well-tolerated. We spent approximately \$130,000 on our Phase I studies in 2003 and approximately \$210,000 on our Phase I studies in 2004.

We commenced Phase II studies in April 2004. The purpose of Phase II studies is to test the safety and efficacy of a drug. The Phase II studies have been completed. We spent approximately \$2,150,000 on our Phase II studies in 2004. The initial analysis of the preliminary data from the Phase II studies indicated that treatment with Psoraxine(R) did not provide any statistically significant clinical improvement of psoriasis in participants of the studies. We are continuing to analyze the data from the Phase II studies to understand why statistical significance at its primary endpoint was not achieved and to evaluate our clinical development options for Psoraxine(R). We spent \$1,635,461 during fiscal year 2005 to complete Phase II studies. For the year ended December 31, 2005, we reflected \$2,510,521 in research and development expenses which included \$114,976 to record the impairment of an intangible asset. For the year ended December 31, 2004, we reflected \$7,689,060 in research and development expenses, including \$4,519,400 related to SkyePharma.

Current Psoriasis Therapies

The topical treatment for psoriasis has been based on the use of emollients, keratolytic agents, coal tar, anthralin, corticosteroids of medium to strong potency and calcipotriene. UVB phototherapy has been used in the treatment of moderate cases of psoriasis. For severe cases, systemic treatments include methotextrate, cyclosporine and oral retinoids. Each of these treatments has variable efficacy, with side effects and cosmetic problems in addition to the failure to prevent frequent relapses.

5

Competition and Psoriasis Treatments in Development

The pharmaceutical and biotechnology industries are intensely competitive. Many companies, including biotechnology, chemical and pharmaceutical companies, are actively engaged in activities similar to ours, including research and development of drugs for the treatment of the same disease as Psoraxine(R). The FDA has approved Amevive, manufactured by Biogen, Raptiva, manufactured by Genentech/Xoma, and Enbrel, manufactured by Amgen and Wyeth, for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients. If we succeed in obtaining FDA approval of Psoraxine(R), Amevive, Raptiva and Enbrel may compete directly with our product. In addition to Biogen, Genentech/Xoma, Amgen and Wyeth, our competitors may include Centocor, Abbott Laboratories and Novartis. Many of these companies have substantially greater financial and other resources, larger research and development staffs, and more extensive marketing and manufacturing organizations than we have. In addition, these companies have more experience in preclinical testing, clinical trials and other regulatory approval procedures than we have. There are also academic institutions, governmental agencies and other research organizations that are conducting research in areas in which we are working. They may also come to develop and market commercial products, either on their own or through collaborative efforts.

Edgar Filing: ASTRALIS LTD - Form 10KSB

We expect to encounter significant competition for any of the pharmaceutical products we develop. Companies that complete clinical trials obtain required regulatory approvals and commence commercial sales of their products before their competitors may achieve a significant competitive advantage.

Developments by others may render our product obsolete or noncompetitive. We will face intense competition from other companies for collaborative arrangements with pharmaceutical and biotechnology companies, for establishing relationships with academic and research institutions and for licenses to additional technologies. These competitors may succeed in developing technologies or products that are more effective than Psoraxine(R).

Government Regulation

The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products. These agencies and other federal, state and local entities regulate research and development activities and testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion of our potential products.

The process required by the FDA before our product candidate, Psoraxine(R), may be marketed in the United States generally involves the following:

- o preclinical laboratory and animal tests;
- o submission of an Investigational New Drug application, which must become effective before clinical trials may begin;
- o adequate and well controlled human clinical trials to establish the safety and efficacy of the proposed drug for its intended use; and
- o FDA approval of a new drug application or biologics license application.

6

The testing and approval process requires substantial time, effort and financial resources, and there can be no assurance that any approvals for Psoraxine(R) or any other potential products will be granted on a timely basis, if at all.

Prior to commencing clinical trials, which are typically conducted in three sequential phases, a company must submit an Investigational New Drug application to the FDA. In March 2003, we filed our Investigational New Drug application for Psoraxine(R) with the FDA. The Investigational New Drug application automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the trial. In such a case, the Investigational New Drug sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. In August 2003, the FDA informed us that we could commence our clinical trials of Psoraxine(R). We have completed Phase I clinical trials in which Psoraxine(R) was found to be generally safe and well-tolerated in Phase I test patients. We also completed 12 months ago a Phase II clinical trial, which did not achieve its primary endpoint for PASI (Psoriasis Area and Severity Index) reduction. We are continuing to analyze the data collected during the Phase II study, including biopsy data indicating cellular level changes that has

Edgar Filing: ASTRALIS LTD - Form 10KSB

not been previously available, to gain a better understanding of the results, and to direct our future efforts.

Although we remain committed to the future clinical development of Psoraxine(R), we may not successfully complete the three phases of clinical trials of Psoraxine(R) within any specific time period, if at all. Furthermore, the FDA or an institutional review board or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.

The results of product development, pre-clinical studies and clinical studies are submitted to the FDA as part of a new drug application or biologics license application. The FDA may deny a new drug application or biologics license application if the applicable regulatory criteria are not satisfied or may require additional clinical data. Even if such data is submitted, the FDA may ultimately decide that the new drug application or biologics license application does not satisfy the criteria for approval. Once issued, the FDA may withdraw product approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches market. In addition, the FDA may require testing and surveillance programs to monitor the effect of approved products which have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs.

Satisfaction of FDA requirements or similar requirements of state, local and foreign regulatory agencies typically takes several years and the actual time required may vary substantially based upon the type, complexity and novelty of the product or indication. Government regulation may delay or prevent marketing of potential products or new indications for a considerable period of time and impose costly procedures upon our activities. Success in early stage clinical trials does not assure success in later stage clinical trials.

Data obtained from clinical activities is not always conclusive and may be susceptible to varying interpretations which could delay, limit or prevent regulatory approval. Even if a product receives regulatory approval, the approval may be significantly limited to specific indications and dosages. Further, even after regulatory approval is obtained, later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. Delays in obtaining, or failures to obtain, additional regulatory approvals for any of our product candidates would have a material adverse effect on our business.

7

Any products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including record-keeping requirements and reporting of adverse experiences with the drug. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with good manufacturing practices, which impose certain procedural and documentation requirements upon us and any third party manufacturers we may utilize. We cannot be certain that our present or future suppliers will be able to comply with the good manufacturing practices, regulations and other FDA regulatory requirements.

Outside the United States, our ability to market a product is contingent upon receiving a marketing authorization from the appropriate regulatory authorities. The requirements governing the conduct of clinical trials, marketing authorization, pricing and reimbursement vary widely from country to

Edgar Filing: ASTRALIS LTD - Form 10KSB

country. At present, foreign marketing authorizations are applied for at a national level, although within the European Union, registration procedures are available to companies wishing to market a product in more than one EU Member State. If the regulatory authority is satisfied that adequate evidence of safety, quality and efficacy has been presented, a marketing authorization will be granted. This foreign regulatory approval process involves all of the risks associated with FDA clearance. To date, we have obtained regulatory approval for clinical testing of Psoraxine(R) in Venezuela, but we have not obtained final regulatory approval for commercial distribution of Psoraxine(R) in Venezuela because we do not have manufacturing facilities in that country and such facilities are required by regulatory authorities in Venezuela before granting commercial approval for a proposed drug.

Intellectual Property

In January 2004 the United States Patent and Trademark Office ("PTO") issued a patent to Dr. Jose O'Daly for the "Compositions and Methods for the Treatment and Clinical Remission of Psoriasis." Under the terms of a license agreement and assignment of license agreement, we have the exclusive right and license to use and exploit this patent. Dr. O'Daly will continue to maintain ownership rights with respect to the patent and patent application. However, Dr. O'Daly has granted us a perpetual, royalty free license to his patent under the agreements, which will terminate only upon the expiration of the patent, or upon the commencement of a bankruptcy or insolvency proceeding involving our company or upon our dissolution or liquidation.

In March 2002, Akiva LLC, an entity controlled by Dr. O'Daly, also filed an application to obtain patent protection internationally under the Patent Cooperation Treaty. In addition, in August 2003, Akiva LLC filed patent applications in the European Union, Australia, Brazil, Canada, Mexico and Japan. We have rights to these applications, which are currently pending, pursuant to the license and assignment of license agreements described above.

In January 2004, Dr. O'Daly filed a patent application with the PTO focusing on the mechanism of action of Psoraxine(R), expanding the claims to include medical indications other than psoriasis, such as Atopic Dermatitis, Psoriatic Arthritis and Rheumatoid Arthritis. In addition, the patent elaborates further on the mechanism of action of Leishmania extracts, which are believed to induce T-cell activation. In January 2004, Dr. O'Daly also filed a second patent relating to a culture medium for parasitic organisms, which is part of our technology platform. Dr. O'Daly has assigned to us the rights in the patent applications. Also, in January 2004, the PTO granted us a federal trademark registration for the mark Psoraxine(R).

Agreements with SkyePharma

We entered into a Purchase Agreement dated as of December 10, 2001 with SkyePharma PLC ("SkyePharma") pursuant to which SkyePharma purchased an aggregate of 2,000,000 shares of our Series A Convertible Preferred Stock, par value \$.001 per share ("Series A Preferred Stock"), for an aggregate purchase price of \$20.0 million. On January 20, 2004, pursuant to our Omnibus Conversion Agreement with SkyePharma, dated January 12, 2004, SkyePharma converted all of its 2,000,000 shares of our Series A Preferred Stock into 25,000,000 shares of our common stock at a conversion price of \$0.80 per share. In March 2005, SkyePharma also acquired an additional 11,160,000 shares of our common stock in a privately negotiated transaction with two private holders. As a result, SkyePharma beneficially owned 49.8% of our common stock at that time. During August 2005, the Company closed on an investment of \$2 million. Consequently

Edgar Filing: ASTRALIS LTD - Form 10KSB

SkyePharma's share of beneficial ownership was approximately 39.7% on December 31, 2005. Additionally, during March 2006, the Company closed on an investment of \$250,000. Consequently SkyePharma's share of beneficial ownership is now approximately 39.8%.

On January 20, 2004, in connection with SkyePharma's conversion of the Series A Preferred Stock, we entered into a Call Option Agreement with SkyePharma, pursuant to which we received the right to repurchase some or all of 12,500,000 shares of our common stock from SkyePharma at a premium to the \$0.80 conversion price. In the event we exercise the call option, the exercise price will be between \$1.28 and \$1.52 per share, depending on the date of exercise. The call option will be exercisable by us for a period commencing upon our achievement of a certain milestone event and ending on January 20, 2007. In June 2004, we assigned the right to purchase 1,250,000 shares under the Call Option Agreement to FPP Capital Advisors as consideration for services it provided in negotiating the Omnibus Conversion Agreement. FPP Capital Advisors is controlled by Fabien Pictet, a member of our Board of Directors.

On January 20, 2004, the closing date of the conversion of SkyePharma's 2,000,000 shares of our Series A Preferred Stock, we, SkyePharma and our other original shareholders amended the Stockholders' Agreement, dated as of December 10, 2001 (the "Amended SkyePharma Stockholders' Agreement"). Pursuant to the Amended SkyePharma Stockholders' Agreement, our board of directors is required to be comprised of at least seven directors and must include at least two independent directors. Per the Amended SkyePharma Stockholders' Agreement, SkyePharma has the right to nominate one director. Michael Ashton is SkyePharma's initial and current nominated director. Until January 20, 2007, Jose Antonio O'Daly has the right to nominate one Director. The Amended SkyePharma Stockholders' Agreement will terminate upon the later of (i) the date on which SkyePharma no longer beneficially owns, in the aggregate, at least 20% of our outstanding common stock or (ii) January 20, 2007. Further, the Amended SkyePharma Stockholders' Agreement may be terminated by the mutual written consent of the parties. Pursuant to the Amended SkyePharma Stockholders' Agreement, SkyePharma is required to vote its shares of our common stock in favor of certain enumerated transactions that have been approved by our board of directors and all of our independent directors. These transactions include (i) the amendment of our certificate of incorporation solely to increase our authorized capital stock, (ii) the adoption or amendment of an employee benefit plan applicable to all employees, (iii) the issuance of additional securities for cash and (iv) the sale of all of our outstanding capital stock or all or substantially all of our assets, or our merger with another entity, provided that SkyePharma will receive the same consideration for its shares as other holders of common stock and will be able to participate in the sale or merger on the same terms as the most favorable terms available to any of our other stockholders and the total consideration for the transaction is greater than \$135 million.

We also entered into two agreements concerning the formulation and development of our initial injectable product candidate, Psoraxine(R), with SkyePharma. Under the terms of the Technology Access Option Agreement, dated December 10, 2001, we paid to SkyePharma a \$5.0 million technology access fee for the option to acquire a license for DepoFoam and other relevant drug delivery technologies owned by SkyePharma. Under the terms of the Technology Access Option Agreement, if we exercise our option, we must pay a royalty of 5% of net sales of all products manufactured or sold that use or exploit the drug delivery technologies that we license from SkyePharma. In addition, if we exercise our option, SkyePharma retains the right during the term of the Technology Access Option Agreement to undertake the manufacture of all of our

Edgar Filing: ASTRALIS LTD - Form 10KSB

products that incorporate or utilize the drug delivery technologies. The option we received under the Technology Access Option Agreement expires on December 10, 2008. The Technology Access Option Agreement may be terminated by either party if (i) the other party commits any irremediable breach of the agreement, (ii) the other party commits any remediable breach and fails to remedy such breach within sixty days of service of notice of the breach, (iii) a court makes an administration order with respect to the other party or any composition in satisfaction of the debts of, or scheme of arrangement of the affairs of, the other party, or (iv) the other party becomes insolvent, has a receiver appointed over any of its assets, enters into any composition with creditors generally or has an order made or resolution passed for it to be wound up. SkyePharma has the right of first negotiation to acquire the worldwide marketing rights to Psoraxine(R). We have evaluated the technology access option fee we paid under the Technology Access Option Agreement, which we have been capitalizing as a research and development intangible asset over a seven-year period, and have determined that as of December 31, 2004, the technology access option fee exceeded its fair market value. Consequently, we recorded as additional research and development costs in 2004 a charge of \$2,797,612 to reflect an impairment of this intangible asset.

In addition, we entered into a Service Agreement, dated December 10, 2001, pursuant to which SkyePharma was to provide us with development, manufacturing, pre-clinical and clinical development services in consideration of \$11 million, of which \$3 million was paid in 2001, with the remaining \$8 million paid primarily during 2002 for second generation Psoraxine(R). The Service Agreement terminated on December 31, 2002. We entered into an Amendment to the Service Agreement with SkyePharma, effective as of January 1, 2003, to extend the term of the Service Agreement and modify the services to be provided by SkyePharma such that SkyePharma continued to provide certain services to us through December 31, 2004, in consideration for payments made during 2002. The agreement expired on December 31, 2004.

Blue Cedar August 2005 Private Placement

On August 19, 2005, we completed a private placement of securities from which we received gross proceeds of approximately \$2,000,000. The transaction consisted of the sale to one accredited investor, Blue Cedar, of units consisting of: (i) 18,181,818 shares of common stock, (ii) warrants to purchase over a 5-year period 18,181,818 shares of common stock with an exercise price of \$0.165 and (iii) warrants to purchase over a 12-month period 12,121,212 shares of common stock with an exercise price of \$0.165. We relied upon the exemption from registration provided under Section 4(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder. The private placement was only made available to one "accredited investor" as defined in Rule 501 of Regulation D. Lipworth Capital Limited acted as our placement agent in connection with the private placement. We paid an 8% fee to our placement agent and issued warrants to purchase 1,454,545 shares of common stock with an exercise price of \$0.165, in connection with the financing in addition to other costs. Additionally, we granted Blue Cedar certain registration rights pursuant to a registration rights agreement, dated as of August 17, 2005, in connection with this transaction. The registration rights agreement required us to file a registration statement within approximately 30 days of the final closing of our private placement covering the resale of all shares included therein, as well as the shares underlying the warrants. Because a registration statement covering the resale of such shares was not filed or effective by December 31, 2005, the date specified in the agreement, we are subject to liquidated damages payments of \$10,000 per month, being 0.5% of the aggregate purchase price plus 10% interest per annum to be paid on unpaid liquidated damages amounts until such time as a registration statement covering the resale of securities sold to Blue Cedar is declared effective by the Securities and Exchange Commission.

Concurrently with the closing of the private placement, we and Blue Cedar entered into the Blue Cedar Stockholder's Agreement. Pursuant to the Blue Cedar Stockholder's Agreement, our Board of Directors is required to be comprised of at least eight directors and Blue Cedar may designate one director to our Board of Directors. Manuel Tarabay is Blue Cedar's initial and current designated director. Further, pursuant to the Blue Cedar Stockholder's Agreement, we agreed not to enter into any service agreement, distribution arrangement or transfer of personnel with any of our stockholders owning more than 10% of the outstanding shares of common stock until we complete Phase II clinical trials of Psoraxine(R), without the prior written consent of Blue Cedar, which shall not be unreasonably withheld. Additionally, for a period of two years following the closing date of the private placement, we granted Blue Cedar certain pre-emptive rights, allowing Blue Cedar to participate in substantially all sales of securities. The Blue Cedar Stockholder's Agreement will terminate upon the earlier of the Blue Cedar Termination Date or August 15, 2008. The "Blue Cedar Termination Date" is the date on which Blue Cedar no longer beneficially owns, in the aggregate, at least 20% of our outstanding common stock.

Other Research and Development Efforts

In addition to our development of Psoraxine(R) for the treatment of psoriasis, we are researching its possible application for the treatment of other conditions, such as eczema, seborrheic dermatitis and leishmaniasis. We are also developing a second product for the treatment of arthritis. We intend to market this product primarily in the United States, although we have not named this product yet and we do not have any approvals from, nor has any application been filed with, the FDA or any foreign governmental regulatory authority for this product. Currently, we do not have any collaborators for this product. We are also engaged in preliminary research of a treatment for transplant rejection.

Employees and Consultants

As of March 31, 2006, we employed five full-time employees, including three scientists and one laboratory technician. We also have seven consultants. We have no part-time employees. None of our employees are covered by a collective bargaining agreement and we believe that our employee relations are good.

FORWARD-LOOKING STATEMENTS

This annual report on Form 10-KSB contains many forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by forward-looking words such as "may", "will", "expect", "anticipate", "believe", "estimate", and "continue" or similar words. You should read statements that contain these words carefully because they discuss our future expectations, contain projections of our future operating results or of our financial condition or state other "forward-looking" information.

We believe that it is important to communicate our future expectations to our investors. However, we may be unable to accurately predict or control events in the future. The factors listed in the sections captioned "Risk Factors" and "Management's Discussion and Analysis or Plan of Operation", as well as any other cautionary language in this annual report, provide examples of risks, uncertainties and events that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements. Before you invest in our common stock, you should be aware that the occurrence of the events described in the "Risk Factors" section, the "Management's Discussion and Analysis or Plan of Operation" section and elsewhere in this annual report could

seriously harm our business.

11

RISK FACTORS

You should carefully consider each of the following risk factors and all of the other information in this report. The following risks relate principally to the Company's business. If any of the following risks actually occur, the business, financial condition or results of operations of the Company could be materially adversely affected. As a result, the market price of shares of the Company's common stock could decline significantly.

We will need to obtain additional funds immediately to support our future operation expenses. Our auditors have expressed uncertainty regarding our ability to continue as a going concern.

As of April 15, 2006 we have \$277,705 in available cash and accounts payable of \$65,067. Based on our current plans, we believe that we have sufficient funds to meet our operating expenses and capital requirements through approximately May 2006. We will need to raise additional funds to continue our operations following that period. Furthermore, substantial additional funds will be needed in order to fund our continued efforts to obtain FDA approval of Psoraxine(R), especially given the failure of our Phase II study to meet its primary endpoint. No assurance can be given that we will be able to obtain financing, or successfully sell assets or stock, or, even if such transactions are possible, that they will be on terms reasonable to us or that they will enable us to satisfy our cash requirements. In addition, raising additional funds by selling additional shares of our capital stock will dilute the ownership interest of our stockholders. If we do not obtain additional funds, we will likely be required to eliminate programs, delay development of our products, alter our business plans, or in the extreme situation, cease operations.

As a result of our losses and the matters described in the preceding paragraph, the Independent Auditors' Report on our financial statements includes a paragraph indicating doubt about our ability to continue as a going concern. The financial statements that accompany this report do not include any adjustments that might be necessary if we are unable to continue as a going concern.

We have no sales; we will not have sales in the foreseeable future; we are in an early stage of development and we may never sell products or become profitable.

We commenced our current operations in 2001 and such operations remain in an early stage of development. We have no products approved for sale and therefore, no means to generate revenue. We have not commercialized any products, had no revenues and had incurred a cumulative net loss of \$53,616,516 as of December 31, 2005 which has increased to date. The cumulative net loss through December 31, 2005 includes non-cash preferred stock dividends of \$22,218,750. We expect that substantial losses will continue for the foreseeable future. In order to obtain revenue from the sales of our product candidate, Psoraxine(R), we must successfully develop, test, obtain regulatory approval for, manufacture, market and eventually sell such product candidate. Our expenses have consisted principally of costs incurred in research and development and from general and administrative costs associated with our operations. We expect our expenses to increase and to continue to incur operating losses for the next several years as we continue our research and development efforts for Psoraxine(R) and any subsequent product candidates.

Edgar Filing: ASTRALIS LTD - Form 10KSB

Commercialization of any of our products will take a significant amount of time and successful commercialization may not occur at all. As a result, we may never become profitable.

Psoraxine(R) may never be approved by the FDA because the results of our Phase II study failed to meet its primary study endpoint.

12

We have focused our development efforts to date on conducting clinical trials for an immuno-stimulatory drug, Psoraxine(R), for the treatment of psoriasis. We recently conducted a randomized, double-blinded, placebo-controlled clinical study involving 120 patients with moderate to severe psoriasis who received six (6) intramuscular injections of Psoraxine(R). The primary endpoint of the study was a specified level of improvement of symptoms measured in accordance with the Psoriasis Area and Severity Index, or PASI, which is a measurement scale that ranks the severity of symptoms of patients suffering from psoriasis. Our initial analysis of the preliminary data showed no statistically significant improvement of those Phase II study patients who received six injections of Psoraxine(R) for a twelve weeks treatment period compared to patients taking a placebo.

The failure of our Phase II study to meet its primary endpoint makes FDA approval of Psoraxine(R) substantially more uncertain. To continue Psoraxine(R)'s development and to obtain FDA approval to market Psoraxine(R), we must complete our analysis of the data from the Phase II study to identify why the Phase II study failed to meet its primary endpoint. We must then undertake additional Phase I or Phase II clinical trials that are adjusted to account for the cause or causes of the initial Phase II study's failure. Although we have already identified a number of possible reasons for the failure to demonstrate efficacy in the recent Phase II trial, and we have also developed a preliminary plan for new clinical studies, there can be no guarantee that we will be able to identify with certainty why our Phase II study failed to meet its primary endpoint and that we will be able to make the needed adjustments for further Phase II studies to be successful. There is also no guarantee that the FDA would approve Psoraxine(R) even if we deem additional clinical trials to be successful.

We have devoted most of our resources to the development of Psoraxine(R) and our business is dependent on its success. In the United States, the marketing of Psoraxine(R) depends on FDA approval of the product. Analyzing the Phase II study data and conducting additional Phase II clinical trials will delay FDA approval. We may also decide to discontinue further clinical trials of Psoraxine(R), which would prevent us from obtaining FDA approval. If we are not able to obtain FDA approval for Psoraxine(R), we would be unable to sell the product and we would have to identify new potential products to develop.

Recent and future changes in senior management and board composition may affect our ability to implement our business plan. In addition we only have one member of our Audit Committee.

On January 25, 2006, we accepted the resignation James Sharpe, effective as of December 31, 2005 with respect to his position as Chief Executive Officer, President and member of the Board of Directors. Michael Garone, our Chief Financial Officer, currently serves as the interim Chief Executive Officer and interim President. Mr. Sharpe is our third Chief Executive Officer and President to resign in an 18 month period. Our ability to implement our business strategy may be adversely affected if we continue to experience unplanned senior management changes in the future or if we are unable to successfully integrate our current and future senior management personnel into our organization.

Edgar Filing: ASTRALIS LTD - Form 10KSB

Additionally there have been changes to the composition of our Board of Directors. In April 2006, we received an announcement from Fabien Pictet that he will be resigning as a member of the Board of Directors. Further, in December 2005, Steven Fulda resigned as a member of the Audit Committee and member of the Board of Directors. As a result of Mr. Fulda's resignation, we only have one member of the Audit Committee. Moreover, our Audit Committee does not contain a member that qualifies as a financial "expert" as defined by Item 401(e) of Regulation S-B of the Exchange Act.

One of our existing stockholders can exert control over us and may not make decisions that further the best interests of all stockholders.

SkyePharma owns approximately 39.8% of our outstanding common stock. As a result, SkyePharma may exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. Furthermore, the interests of SkyePharma may not always coincide with our interests or the interests of other stockholders and accordingly, they could cause us to enter into transactions or agreements which we would not otherwise consider. In addition, this concentration of ownership may delay or prevent a merger or acquisition resulting in a change in our control might affect the market price of our common stock, even when such a change in control may be in the best interest of all stockholders.

13

We may not be successful in the development and commercialization of products.

We may not develop products that prove to be safe and effective, that meet applicable regulatory standards or that we can manufacture at reasonable costs or market successfully. Successful products will require significant development and investment, including testing, to demonstrate their safety and efficacy prior to their commercialization. We have not proven our ability to develop and commercialize products. We must conduct a substantial amount of additional research and development before any regulatory authority will approve our initial product candidate, Psoraxine(R). Our research and development and clinical trials may not confirm the safety and efficacy of our products, in which case regulatory authorities may not approve them. In addition, even if we successfully complete our research and development efforts, Psoraxine(R) may not perform in the manner we anticipate, and may not be accepted for use by the public.

Substantial additional funds and effort will be necessary for further development and commercialization of Psoraxine(R).

Our initial product candidate, Psoraxine(R), will require the commitment of substantial resources to move it towards commercialization. Before obtaining regulatory approvals for the commercial sale of Psoraxine(R), we must demonstrate the safety and efficacy of our product candidate through preclinical testing and clinical trials. Conducting clinical trials involves a lengthy, expensive and uncertain process. Completion of clinical trials may take several years or more. The length of time generally varies substantially according to the type, complexity, novelty and intended use of the product. If we or the U.S. Food and Drug Administration believe that our clinical trials expose participating patients to unacceptable health risks, we may suspend such trials.

We may encounter problems in our studies which will cause us or the FDA to delay or suspend the studies. Some of the factors that may delay our commencement and rate of completion of clinical trials include:

Edgar Filing: ASTRALIS LTD - Form 10KSB

- o ineffectiveness of the study compound, or perceptions by physicians that the compound will not successfully treat a particular indication;
- o inability to manufacture sufficient quantities of compounds for use in clinical trials;
- o failure of the FDA to approve our clinical trial protocols;
- o slower than expected rate of patient recruitment;
- o unforeseen safety issues; or
- o government or regulatory delays.

The failure of future clinical trials may harm our business, financial condition and results of operations.

14

Our potential therapeutic products face a lengthy and uncertain regulatory process. If we do not obtain regulatory approval of our potential products, we will not be able to commercialize these products.

The FDA must approve any therapeutic product before it can be marketed in the United States. Before we obtain FDA approval of a new drug application or biologics license application, the product must undergo extensive testing, including animal and human clinical trials, which can take many years and requires substantial expenditure. Data obtained from such testing may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. In addition, changes in regulatory policy for product approval during the period of product development and regulatory agency review of each submitted new drug application may cause delays or rejections. We must devote a substantial amount of time and resources in the regulatory process in order to obtain regulatory approval of our initial product candidate, Psoraxine (R).

Because our initial product candidate, Psoraxine(R), involves the application of new technologies and may be used upon new therapeutic approaches, government regulatory authorities may subject this product to more rigorous review and may grant regulatory approvals more slowly for this product than for products using more conventional technologies. We have not received approval from the FDA to market or commercialize Psoraxine(R). The regulatory agencies of foreign governments must also approve any therapeutic product we may develop before the product can be sold in those countries. To date, although we have obtained regulatory approval for clinical testing of Psoraxine(R) in Venezuela, we have not sought, nor have we obtained, regulatory approval for the commercialization of Psoraxine(R) in Venezuela because, among other things, we do not have manufacturing facilities in that country and such facilities are required by regulatory authorities in Venezuela before granting commercial approval for a proposed drug.

Even after investing significant time and resources, we may not obtain regulatory approval for our product. If we do not receive regulatory approval, we cannot sell the product. Even if we receive regulatory approval, this approval may place limitations on the indicated uses for which we can market the product. Further, after granting regulatory approval, regulatory authorities subject a marketed product and its manufacturer to continual review, and discovery of previously unknown problems with a product or manufacturer may result in restrictions on the product, manufacturer and manufacturing facility,

Edgar Filing: ASTRALIS LTD - Form 10KSB

including withdrawal of the product from the market. In certain countries, regulatory agencies also set or approve prices.

Even if product candidates emerge successfully from clinical trials, we may not be able to successfully manufacture, market and sell them.

We have not successfully completed clinical trials of Psoraxine(R). If Psoraxine(R) emerges successfully from clinical trials and obtains regulatory approval, we will either commercialize products resulting from our proprietary programs directly or through licensing arrangements with other companies. We have no experience in manufacturing and marketing, and we currently do not have the resources or capability to manufacture, market or sell our products on a commercial scale. In order to commercialize Psoraxine(R) directly, we would need to develop or obtain through outsourcing arrangements the capability to manufacture, market and sell products. In addition, we currently do not have any agreements for the marketing or sale of any of our products and we may not be able to enter into such agreements on commercially reasonable terms, or at all.

We license and do not own our intellectual property. Any inability to protect our proprietary technologies adequately could harm our competitive position.

15

We license, and do not own, the intellectual property rights to Psoraxine(R). Dr. Jose Antonio O'Daly is the owner of the patent for Psoraxine(R). Under the terms of a license agreement and assignment of license agreement, we have the right to use any patent issued pursuant to Dr. O'Daly's patent application. We also have rights to other patents filed by Dr. O'Daly under the terms of our employment agreement with him. Our success will depend in part on our ability to obtain patents and maintain adequate protection of other intellectual property for our technologies and products in the United States and other countries. If we do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate our competitive advantage. The laws of some foreign countries do not protect our proprietary rights to the same extent as the laws of the United States, and we may encounter significant problems in protecting our proprietary rights in these foreign countries.

The patent positions of biotechnology companies, including our patent positions, involve complex legal and factual questions and, therefore, validity and enforceability cannot be predicted with certainty. Patents may be challenged, deemed unenforceable, invalidated or circumvented. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that we cover our proprietary technologies with valid and enforceable patents or we effectively maintain such proprietary technologies as trade secrets. We will apply for patents covering both our technologies and product candidates as we deem appropriate. However, we may fail to apply for patents on important technologies or products in a timely fashion, or at all, and in any event, the applications we do file may be challenged and may not result in issued patents. Any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. Furthermore, others may independently develop similar or alternative technologies or design around our patented technologies. In addition, others may challenge or invalidate our patents, or our patents may fail to provide us with any competitive advantages. If we encounter challenges to the use or validity of any of our patents, resulting in litigation or administrative proceedings, we would incur substantial costs and the diversion of management in defending the patent. In addition, we do not control the patent prosecution of technology that we license from others. Accordingly, we cannot exercise the same degree of

Edgar Filing: ASTRALIS LTD - Form 10KSB

control over this intellectual property as we would over technology we own.

We rely upon trade secrets protection for our confidential and proprietary information. We have taken measures to protect our proprietary information. These measures may not provide adequate protection for our trade secrets or other proprietary information. We seek to protect our proprietary information by entering into confidentiality agreements with employees, collaborators and consultants. Nevertheless, employees, collaborators or consultants may still disclose our proprietary information, and we may not be able to meaningfully protect our trade secrets. In addition, others may independently develop substantially equivalent proprietary information or techniques or otherwise gain access to our trade secrets.

Many potential competitors which have greater resources and experience than we do may develop products and technologies that could make ours obsolete.

Companies in the biotechnology industry face rapid technological change in a rapidly evolving field. Our future success will depend on our ability to maintain a competitive position with respect to technological advances. Rapid technological development by others may result in our products and technologies becoming obsolete.

We face, and will continue to face, intense competition from organizations such as large biotechnology and pharmaceutical companies, as well as academic and research institutions and government agencies. Our competitors may include Biogen, Genentech/Xoma, Amgen, Wyeth, Abbott Laboratories and Novartis. These organizations may develop technologies that provide superior alternatives to our technologies. Further, our competitors may be more effective at implementing their technologies to develop commercial products.

16

Any products that we develop through our technologies will compete in multiple, highly competitive markets. Many of the organizations competing with us in the markets for such products have greater capital resources, research and development and marketing staffs, facilities and capabilities, and greater experience in obtaining regulatory approvals, product manufacturing and marketing. Accordingly, our competitors may be able to develop technologies and products more easily, which would render our technologies and products obsolete and noncompetitive.

If we lose our key personnel or fail to attract and retain additional personnel, we may be unable to discover and develop our products.

We depend on the services of Dr. Jose Antonio O'Daly, the Chairman of our Board of Directors and our Chief Scientific Officer, and Michael Garone, interim Chief Executive Officer, interim President and Chief Financial Officer, the loss of whose services would adversely impact the achievement of our objectives. To execute our business plan fully it is essential that we retain these executives. In addition, recruiting and retaining qualified scientific personnel to perform future research and development work will be critical to our success. Although we believe we can successfully attract and retain qualified personnel, we face intense competition for experienced scientists. Failure to attract and retain skilled personnel would prevent us from pursuing collaborations and developing our products and core technologies to the extent otherwise possible.

Our planned activities will require additional expertise. These activities will require the addition of new personnel, including management, and the development of additional expertise by existing management personnel. The inability to acquire or develop this expertise could impair the growth, if any,

Edgar Filing: ASTRALIS LTD - Form 10KSB

of our business.

If we face claims in clinical trials of a drug candidate, these claims will divert our management's time and we will incur litigation costs.

We face an inherent business risk of clinical trial liability claims in the event that the use or misuse of Psoraxine(R) results in personal injury or death. We may experience clinical trial liability claims if our drug candidates are misused or cause harm before regulatory authorities approve them for marketing. Although, we currently maintain clinical liability insurance coverage, it may not sufficiently cover any claims made against us and may not be available in the future on acceptable terms, if at all. Any claims against us, regardless of their merit, could strain our financial resources in addition to consuming the time and attention of our management. Law suits for any injuries caused by our products may result in liabilities that exceed our total assets.

Some of our existing stockholders can exert control over us and many not make decisions that further the best interests of all stockholders.

Our officers, directors and principal stockholders (greater than 5% stockholders) together control approximately 77.7% of our outstanding common stock. As a result, these stockholders, if they act individually or together, may exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. Furthermore, the interests of this concentration of ownership may not always coincide with our interests or the interests of other stockholders and accordingly, they could cause us to enter into transactions or agreements which we would not otherwise consider. In addition, this concentration of ownership may delay or prevent a merger or acquisition resulting in a change in control of us and might affect the market price of our common stock, even when such a change in control may be in the best interest of all stockholders.

17

The market price of our common stock may be highly volatile.

The market price of our common stock has been and will likely continue to be highly volatile. From the date trading of our common stock commenced until March 31, 2006, the range of our stock price has been between \$0.02 and \$7.15. Factors including announcements of technological innovations by us or other companies, regulatory matters, new or existing products or procedures, concerns about our financial position, operating results, government regulation, or developments or disputes relating to agreements, patents or proprietary rights may have a significant impact on the market price of our stock. In addition, potential dilutive effects of future sales of shares of common stock by us, our stockholders, or the holders of warrants and options, could have an adverse effect on the price of our common stock.

A large number of shares of our common stock may be sold in the market, which may depress the market price of our common stock.

Sales of substantial amounts of our common stock in the public market, or the perception that these sales might occur, could materially and adversely affect the market price of our common stock or our future ability to raise capital through an offering of our equity securities. We have an aggregate of 91,454,873 shares of our common stock outstanding. If all options and warrants currently outstanding to purchase shares of our common stock are exercised, there will be approximately 145,223,895 shares of our common stock outstanding.

Edgar Filing: ASTRALIS LTD - Form 10KSB

Of the outstanding shares, up to 73,173,055 shares are freely tradable without restriction or further registration under the Securities Act, unless the shares are held by one of our "affiliates" as such term is defined in Rule 144 of the Securities Act. The remaining shares may be sold only pursuant to a registration statement under the Securities Act or an exemption from the registration requirements of the Securities Act. The sale and distribution of these shares may cause a decline in the market price of our common stock.

Our common stock qualifies as a "penny stock" under SEC rules which may make it more difficult for our stockholders to resell their shares of our common stock.

Our common stock trades on the OTC Bulletin Board. As a result, the holders of our common stock may find it more difficult to obtain accurate quotations concerning the market value of the stock. Stockholders also may experience greater difficulties in attempting to sell the stock than if it were listed on a stock exchange or quoted on the Nasdaq National Market or the Nasdaq Small-Cap Market. Because our common stock does not trade on a stock exchange or on the Nasdaq National Market or the Nasdaq Small-Cap Market, and the market price of the common stock is less than \$5.00 per share, the common stock qualifies as a "penny stock." SEC Rule 15c-9 under the Exchange Act imposes additional sales practice requirements on broker-dealers that recommend the purchase or sale of penny stocks to persons other than those who qualify as an "established customer" or an "accredited investor." This includes the requirement that a broker-dealer must make a determination on the appropriateness of investments in penny stocks for the customer and must make special disclosures to the customer concerning the risks of penny stocks. Application of the penny stock rules to our common stock could adversely affect the market liquidity of the shares, which in turn may affect the ability of holders of our common stock to resell the stock.

Item 2. Description of Property

18

We lease our executive offices and research laboratory located at 75 Passaic Avenue, Fairfield, New Jersey 07004. The yearly rent for such office and laboratory space is \$110,400.

Item 3. Legal Proceedings

Neither we, nor any of our properties, are presently a party to any material legal proceeding, nor, to our knowledge, is any such proceeding threatened against us or any of our properties.

Item 4. Submission of Matters to a Vote of Security Holders.

No matters were submitted for a vote of our shareholders during the fourth quarter of fiscal 2005.

PART II

Item 5. Market For Common Equity, Related Stockholder Matters and Small Business Issuer Purchases of Equity Securities

Market Information

Our common stock is traded on the Over-the-Counter Bulletin Board ("OTC Bulletin Board") under the symbol ASTR.OB. The following table sets forth, for the periods indicated, the range of high and low bid quotations for shares of

Edgar Filing: ASTRALIS LTD - Form 10KSB

our common stock as quoted on the OTC Bulletin Board. The reported bid quotations reflect inter-dealer prices, without retail markup, markdown or commissions, and may not necessarily represent actual transactions.

2004 ----	High ----	Low ---
First Quarter	\$1.66	\$0.64
Second Quarter	\$1.46	\$1.04
Third Quarter	\$1.05	\$0.51
Fourth Quarter	\$0.85	\$0.42
2005 ----		
First Quarter	\$0.84	\$0.20
Second Quarter	\$0.40	\$0.20
Third Quarter	\$0.25	\$0.15
Fourth Quarter	\$0.16	\$0.02

Holder of Common Stock

As of March 31, 2006, there were approximately 89 record holders of our common stock.

19

Dividends

We have never paid or declared a cash dividend on our common stock. We intend, for the foreseeable future, to retain all future earnings for use in our business. The amount of dividends we pay in the future, if any, will be at the discretion of our Board of Directors and will depend upon our earnings, capital requirements, financial condition and other relevant factors.

Equity Compensation Plan Information

The following table provides information with respect to the equity securities that are authorized for issuance under our compensation plans as of December 31, 2005:

Equity Compensation Plan Information at December 31, 2005

	Number of securities to be issued upon the exercise of outstanding options, warrants and rights (a)	Weighted-average exercise price of outstanding options, warrants and rights (b)	
Equity compensation plans approved by securities holders	1,454,000	\$0.26-\$2.50	
Equity compensation plans not approved by securities holders	0	0	
Total	1,454,000	\$0.26-\$2.50	

Edgar Filing: ASTRALIS LTD - Form 10KSB

Recent Sales of Unregistered Securities

On March 31, 2006, the Company closed a private placement of securities from which it received proceeds of \$250,000. In connection with such private placement, the Company issued to Blue Cedar, an accredited investor and currently a stockholder of the Company, (i) a convertible promissory note in the principal amount of \$250,000, convertible into shares of the Company's Common Stock at \$0.09 per share, and (ii) a warrant to purchase 2,777,778 shares of Common Stock. Lipworth Capital Limited acted as the placement agent in connection with this private placement. The securities offered and sold in this private placement were sold in reliance on an exemption from the registration requirements under Regulation D of the Securities Act of 1933.

On August 19, 2005, the Company closed a private placement of securities from which they received gross proceeds of approximately \$2,000,000. The transaction consisted of the sale to one accredited investor, Blue Cedar, of units consisting of: (i) 18,181,818 shares of Common Stock, (ii) warrants to purchase over a 5-year period 18,181,818 shares of common stock with an exercise price of \$0.165 and (iii) warrants to purchase over a 12-month period 12,121,212 shares of common stock with an exercise price of \$0.165. The Company relied upon the exemption from registration provided under Section 4(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder. The private placement was only made available to one "accredited investor" as defined in Rule 501 of

20

Regulation D and the required number of manually executed originals and true copies of Form D were and timely filed with the Securities and Exchange Commission. Lipworth Capital Limited acted as the placement agent in connection with the private placement. The Company paid an 8% fee to the placement agent and issued warrants to purchase 1,454,545 shares of common stock with an exercise price of \$0.165, in connection with the financing in addition to other costs. Additionally, the Company granted Blue Cedar certain registration rights pursuant to a registration rights agreement, dated as of August 17, 2005, in connection with this transaction. The registration rights agreement required the Company to file a registration statement within approximately 30 days of the final closing of the private placement covering the resale of all shares included therein, as well as the shares underlying the warrants. Because a registration statement covering the resale of such shares was not filed or effective by December 31, 2005, the date specified in the agreement, the Company is subject to liquidated damages payments of \$10,000 per month, being 0.5% of the aggregate purchase price plus 10% interest per annum to be paid on unpaid liquidated damages amounts until such time as a registration statement covering the resale of securities sold to Blue Cedar is declared effective by the Securities and Exchange Commission.

On June 4, 2005, the Company issued 20,000 options to a director. The options were issued with an exercise price of \$0.28 and with a term of 10 years. The options shall vest over three years, with 25% vesting on the date of the grant and 25% vesting on the anniversary of the grant date until fully vested.

On April 11, 2005, the Company issued 50,000 options to a newly elected director. The options were issued with an exercise price of \$0.26 and with a term of 10 years. The options shall vest over three years, with 25% vesting on the date of the grant and 25% vesting on the anniversary of the grant date until fully vested.

On February 2, 2005, the Company issued 20,000 options to a director. The

Edgar Filing: ASTRALIS LTD - Form 10KSB

options were issued with an exercise price of \$0.69 and with a term of 10 years. The options shall vest over three years, with 25% vesting on the date of the grant and 25% vesting on the anniversary of the grant date until fully vested.

In January 2005, the Company issued 100,000 shares of the Company's common stock along with 728,000 options to James Sharpe, the Company's former Chief Executive Officer and President. The options were issued with an exercise price of \$0.70 with a term of ten years. The options vest over three years, with 25% vesting on the date of the grant and 25% vesting on the anniversary of the grant date until fully vested. Mr. Sharpe resigned as Chief Executive Officer, President and member of the Board of Directors as of January 25, 2006, with an effective resignation date of December 31, 2005.

In the first quarter of 2005 SkyePharma purchased the 11,160,000 shares of common stock from Mike Ajnsztajn and Gaston Liebhaber. Consequently, as of March 3, 2005 SkyePharma owned approximately 49.7% of the Company's outstanding common stock.

On December 10, 2004, we entered into an Employment Agreement with Jose Antonio O'Daly, the Chairman of our Board of Directors and our Chief Scientific Officer. Pursuant to the terms of the Employment Agreement, we granted Dr. O'Daly options to purchase 728,000 shares of our common stock at an initial exercise price of \$0.70 per share. The options were fully vested upon grant and expire in ten years.

On July 9, 2004, Steven Fulda, a former member of our Board of Directors, exercised options to purchase 25,000 shares of our common stock at \$0.45 per share.

On July 2, 2004, we granted options to purchase 50,000 shares of our common stock at an exercise price of \$1.00 per share to Samuel Barnett, one of our Directors. Twenty-five percent of the options were vested upon the date of grant, and options to purchase an additional 12,500 shares of our common stock will vest each year thereafter on the anniversary of the date of grant. The options will expire in four years.

21

In June 2004, we issued units consisting of 150,000 shares of common stock and warrants to purchase 150,000 shares of common stock to FPP Capital Advisors, which is controlled by Fabien Pictet, a member of our Board of Directors, in consideration for services valued at \$75,000 that were rendered to us in negotiating a Call Option Agreement, dated January 12, 2004, between us and SkyePharma. The 150,000 warrants have an exercise price of \$0.73 per share of common stock and expire five years from the date of issue. Under the Call Option Agreement, SkyePharma agreed that up to 12,500,000 shares of its common stock issued upon conversion of the Series A Convertible Preferred Stock will be subject to a call option, exercisable at our discretion upon completion of agreed upon milestones and ending on January 20, 2007. In the event we exercise the call option, the exercise price will be between \$1.28 and \$1.52 per share, depending on the date of exercise. We assigned to FPP Capital Advisors the right to purchase 1,250,000 shares of our common stock pursuant to the Call Option Agreement. We relied on the exemption from registration with the Securities and Exchange Commission provided under Section 4(2) of the Securities Act and Rule 506 of Regulation D under the Securities Act.

On January 20, 2004 and February 19, 2004, we sold to accredited investors units consisting of an aggregate of 10,459,866 shares of common stock and warrants to purchase 10,459,866 shares of common stock for an aggregate purchase price of approximately \$5.23 million. The warrants have an exercise price of

Edgar Filing: ASTRALIS LTD - Form 10KSB

\$0.73 and expire in four years. We relied on the exemption from registration under Regulation D of the Securities Act. In July 2004, we filed a registration statement under the Securities Act covering the resale of the shares purchased and the shares issuable upon exercise of the warrants.

In connection with the private placements on January 20, 2004 and February 19, 2004, FPP Capital Advisors received a consulting fee of \$261,496, warrants to purchase 418,394 shares of our common stock at \$0.50 per share and warrants to purchase 418,394 shares of our common stock at \$0.73 per share. The warrants expire in four years. FPP Capital Advisors will be paid an additional consulting fee equal to 5% of the proceeds we receive upon exercise of the warrants issued in the private placements. We relied on the exemption from registration with the Securities and Exchange Commission provided under Section 4(2) of the Securities Act and Rule 506 of Regulation D under the Securities Act.

On January 20, 2004, pursuant to an Omnibus Conversion Agreement, dated January 12, 2004, between us and SkyePharma, SkyePharma converted all of its 2,000,000 outstanding shares of Series A Convertible Preferred Stock into 25,000,000 shares of our common stock at a conversion price of \$0.80 per share. As a result of this conversion, we no longer have any shares of preferred stock outstanding and SkyePharma no longer has rights as a preferred stockholder. We relied on the exemption from registration with the Securities and Exchange Commission provided under 4(2) of the Securities Act and Rule 506 of Regulation D under the Securities Act.

During the thirteen month period ending January 31, 2003, SkyePharma purchased 2,000,000 shares of our Series A Convertible Preferred Stock, par value \$.001 per share pursuant to a Purchase Agreement dated as of December 10, 2001, at a purchase price of \$10.00 per share, or an aggregate purchase price of \$20.0 million. We sold these shares in reliance on the exemption from registration with the Securities and Exchange Commission provided under Section 4(2) and Rule 506 of Regulation D under the Securities Act.

On January 10, 2002, Mike Ajnsztajn, our former Chief Executive Officer and a former member of our Board of Directors, Jose Antonio O'Daly, the Chairman of our Board of Directors and our Chief Scientific Officer, and Gaston Liebhaber, a former member of our Board of Directors, transferred, respectively, 175,000, 275,000 and 50,000 shares of our common stock owned by them to Manuel Tarabay for consulting services rendered by Mr. Tarabay in connection with their efforts to raise capital for our company. Messrs. Ajnsztajn, O'Daly and Liebhaber relied on the exemption from registration afforded by Section 4(2) of the Securities Act.

22

Item 6. Management's Discussion and Analysis or Plan of Operation

The following discussion of our financial condition and plan of operation should be read in conjunction with our financial statements and the related notes included elsewhere in this annual report on Form 10-KSB. This annual report contains certain statements of a forward-looking nature relating to future events or our future financial performance. We caution prospective investors that such statements involve risks and uncertainties, and that actual events or results may differ materially. In evaluating such statements, prospective investors should specifically consider the various factors identified in this annual report, including the matters set forth under the caption "Risk Factors" which could cause actual results to differ materially from those indicated by such forward-looking statements. We disclaim any obligation to update information contained in any forward-looking statement.

Edgar Filing: ASTRALIS LTD - Form 10KSB

Overview

We are a development stage biotechnology company engaged primarily in the research and development of treatments for immune system disorders and skin diseases. Our initial product candidate, Psoraxine(R), is a protein extract used for the treatment of the skin disease psoriasis.

Currently, we are engaged in the following activities to further our development efforts of our initial product candidate:

- o Ongoing research and development of Psoraxine(R);
- o Conducting clinical trials to obtain the approval of the United States Food and Drug Administration for the marketing of Psoraxine(R); and
- o Development of the technology underlying Psoraxine(R) for the treatment of indications other than psoriasis, such as eczema, seborrheic dermatitis and leishmaniasis.

Fiscal year ended December 31, 2005 compared to fiscal year ended December 31, 2004.

For fiscal year ended December 31, 2005:

On August 19, 2005, the Company closed a private placement of securities from which they received gross proceeds of approximately \$2,000,000. The transaction consisted of the sale to one accredited investor, Blue Cedar, of units consisting of: (i) 18,181,818 shares of common stock, (ii) warrants to purchase over a 5-year period 18,181,818 shares of common stock with

23

an exercise price of \$0.165 and (iii) warrants to purchase over a 12-month period 12,121,212 shares of common stock with an exercise price of \$0.165. The Company relied upon the exemption from registration provided under Section 4(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder. The private placement was only made available to one "accredited investor" as defined in Rule 501 of Regulation D and the required number of manually executed originals and true copies of Form D were and timely filed with the Securities and Exchange Commission. Lipworth Capital Limited acted as the placement agent in connection with the private placement. The Company paid an 8% fee to the placement agent and issued warrants to purchase 1,454,545 shares of common stock with an exercise price of \$0.165, in connection with the financing in addition to other costs. Additionally, the Company granted Blue Cedar certain registration rights pursuant to a registration rights agreement, dated as of August 17, 2005, in connection with this transaction. The registration rights agreement required the Company to file a registration statement within approximately 30 days of the final closing of the private placement covering the resale of all shares included therein, as well as the shares underlying the warrants. Because a registration statement covering the resale of such shares was not filed or effective by December 31, 2005, the date specified in the agreement, the Company is subject to liquidated damages payments of \$10,000 per month, being 0.5% of the aggregate purchase price plus 10% interest per annum to be paid on unpaid liquidated damages amounts until such time as a registration statement covering the resale of securities sold to Blue Cedar is declared effective by the Securities and Exchange Commission.

In August 2005, the Board of Directors approved a resolution, subject to shareholder approval, to increase the authorized number of shares of common stock by 200,000,000 shares. The Company has not yet held a stockholders meeting

Edgar Filing: ASTRALIS LTD - Form 10KSB

to approve such amendment.

For the fiscal year ended December 31, 2005, we had no revenue from operations and incurred operating expenses of \$4,168,452 which consisted primarily of:

- o Research and development costs of \$2,510,521, including \$1,635,461 that we incurred to complete our Phase II clinical study.
- o General and administrative costs of approximately \$1,657,931, including professional fees and our general corporate expenditures.

In December 2005, we received \$306,921 in cash from the sale of a portion of our tax related net operating losses ("NOLS") under the State of New Jersey's Technology Business Tax Certificate Transfer Program. The program is an initiative adopted by the New Jersey State legislature that allows qualified technology and biotechnology businesses in New Jersey to sell unused amounts of NOLS and defined research and development tax credits for cash.

In the fourth quarter of 2005 we recognized \$83,000 as the fair value of the liquidated damages penalty provision payments in connection with the Registration Rights Agreement with Blue Cedar.

As a result, during the fiscal year ended December 31, 2005, we incurred a net loss of \$3,914,159.

For fiscal year ended December 31, 2004:

On January 20, 2004 we closed a private placement from which we received gross proceeds of approximately \$4.08 million. The transaction consisted of the sale to accredited investors of units consisting of 8,159,964 shares of common stock and warrants to purchase 8,159,964 shares of common stock. Concurrently with this transaction, SkyePharma converted all of its outstanding shares of Series A Preferred Stock into 25,000,000 shares of common stock at a reduced conversion price of \$0.80 per share. In accordance with Statement of Financial Auditing Standard 84, "Induced Conversions of Convertible Debt, an Amendment of APB Opinion No. 26," we recorded this conversion transaction as a non-cash preferred stock dividend in January 2004 in the amount of \$10,750,000.

24

On February 19, 2004, we held a second closing for our private placement from which we received gross proceeds of approximately \$1.15 million. The transaction consisted of the sale to accredited investors of units consisting of 2,299,902 shares of common stock and warrants to purchase 2,299,902 shares of common stock. In connection with our private placements and the conversion of SkyePharma's Series A Preferred Stock, SkyePharma agreed that 12,500,000 shares of the common stock issued upon conversion will be subject to a right of repurchase by us under certain circumstances at a premium to the conversion price. We assigned the right to purchase 1,250,000 of these shares to FPP Capital Advisors as consideration for services it provided to us in negotiating the Series A Preferred Stock conversion by SkyePharma. Accordingly, we recorded a non-cash charge of \$376,508 in June 2004 in connection with this assignment.

In February 2004, in connection with the private placement, FPP Capital Advisors received a consulting fee of \$261,496, warrants to purchase 418,394 shares of our common stock at \$0.50 per share and warrants to purchase 418,394 shares of our common stock. In June 2004, we issued units consisting of 150,000 shares of common stock and warrants to purchase 150,000 shares of common stock to FPP Capital Advisors in consideration for services rendered to us in

Edgar Filing: ASTRALIS LTD - Form 10KSB

negotiating our right to repurchase 12,500,000 shares of common stock from SkyePharma.

For the fiscal year ended December 31, 2004, we had no revenue from operations and incurred operating expenses of \$9,580,307 which consisted primarily of:

- o Research and development costs of \$7,689,060, including \$2,360,000 that we incurred to conduct our Phase I and Phase II clinical studies, \$1,007,500 for services provided by SkyePharma under our Service Agreement with them, amortization of approximately \$714,288 of the technology option license under our Technology Access Option Agreement with SkyePharma as an intangible asset over its seven-year life, and a charge of \$2,797,612 to record an impairment of the technology option license.
- o General and administrative costs of approximately \$1,860,844, including professional fees and our general corporate expenditures.

In December 2004, we received \$293,461 in cash from the sale of a portion of our tax related NOLS under the State of New Jersey's Technology Business Tax Certificate Transfer Program. The program is an initiative adopted by the New Jersey State legislature that allows qualified technology and biotechnology businesses in New Jersey to sell unused amounts of NOLS and defined research and development tax credits for cash.

As a result, during the fiscal year ended December 31, 2004, we incurred a net loss of \$20,037,568, which also included a non-cash preferred stock dividend of \$10,750,000.

The Next Twelve Months

At December 31, 2005 we had cash balances of \$633,468, which as of March 31, 2006 was substantially depleted but with the addition of funds from our sale of convertible notes and warrants, we estimate will last us through approximately May 2006, and no marketable securities. On March 31, 2006, the Company closed a private placement of securities from which it received proceeds of \$250,000. In connection with such private placement, the Company issued to Blue Cedar, an accredited investor and currently a stockholder of the Company, (i) a convertible promissory note in the principal amount of \$250,000, convertible into shares of the Company's Common Stock at \$0.09 per share, and (ii) a warrant to purchase 2,777,778 shares of Common Stock. Lipworth Capital Limited acted as the placement agent in connection with this private placement. The securities offered and sold in this private placement were sold in reliance on an exemption from the registration requirements under Regulation D of the Securities Act of 1933. At March 31, 2006 the Company had cash balances of \$289,607 which we estimate will last us through approximately May 2006 and no marketable securities.

Based on our current operating plan, we anticipate conducting the following activities and using our cash over the course of the next twelve months as follows:

- o Our primary focus is to further development efforts of our initial product candidate, Psoraxine(R). In March 2005, the Company announced that the Phase II study of its novel immuno-stimulatory product for the treatment of Psoriasis did not meet the primary study endpoint upon completion of the treatment phase of the study. In the study, Psoraxine(R) was found to be safe and well-tolerated. Accordingly, we analyzed the data and

Edgar Filing: ASTRALIS LTD - Form 10KSB

developed an hypothesis that may explain why we received these unexpected results. In this regard, we are implementing cost containment measures; realigning development activities to focus on such things as formulation, manufacturing, analytical protocols and potency; and we are testing the hypothesis to explain unexpected results and determine the best course for future development. We remain committed to Psoraxine(R) and its future development, and hope to see it return to Phase II clinical trials in 2006.

- o We intend to implement our business plan and facilitate the operations of our company. The business plan will be implemented in phases: during the first phase we expect to test the hypothesis developed recently to assess causes for unexpected results in the Phase II trial. During the second phase, test results will be used to design and begin a new Phase II trial. We expect that we would be required to incur expenses of approximately \$750,000 to third parties in connection with continuing development of Psoraxine(R).
- o We will spend approximately \$450,000 to pay management salaries and salaries of employees, a portion of which is treated as research and development expense.
- o We also expect to expend approximately \$700,000 for our general administrative and working capital requirements.
- o In connection with the August 2005 Blue Cedar private placement, because a registration statement covering the resale of the Blue Cedar shares was not filed or effective by December 31, 2005, we are required to pay liquidated damages payments of \$10,000 per month, being 0.5% of the aggregate purchase price plus 10% annum interest until such time as a registration statement covering the resale of securities sold to Blue Cedar is declared effective by the Securities and Exchange Commission.
- o We will need to raise additional funds immediately to continue our operations for the period following the first quarter of 2006 and to fund any of the activities described above. Furthermore, substantial additional funds will be needed in order to fund our continued efforts to obtain FDA approval of Psoraxine(R). No assurance can be given that we will be able to obtain financing on terms that we find acceptable, or that they will enable us to satisfy our cash requirements. In addition, raising additional funds by selling additional shares of our capital stock will dilute the ownership interest of our stockholders. Presently, neither our management nor our bankers have identified new sources of capital. If we do not obtain additional funds, we will likely be required to cease operations.

Item 7. Financial Statements

The financial statements required by this Item 7 begin at page F-1 of this annual report.

Item 8. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.

None.

Item 8A. Controls and Procedures

(a) Evaluation of disclosure controls and procedures.

Based on their evaluation as of the end of the period covered by this Annual Report on Form 10-KSB, our interim Chief Executive Officer, interim

Edgar Filing: ASTRALIS LTD - Form 10KSB

President and Chief Financial Officer have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the

26

Exchange Act) are not effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms.

As a result of the audit of our 2005 financial statements by our independent auditors we have become aware of certain deficiencies that exist in the design and operation of our internal controls over financial reporting that our independent auditors consider to be material weaknesses under standards of the Public Company Accounting Oversight Board (PCAOB).

Our independent auditors identified certain errors in the financial statements in the current period that were not initially identified by the Company's internal control over financial reporting. The aggregate amount of these errors was material to our financial statements and therefore represent a material weakness in our internal control over financial reporting. Upon being notified of these errors we corrected the information included in the financial statements before such statements were filed with the Securities and Exchange Commission or disclosed publicly to any parties.

Management will review the system of internal controls and take steps to insure information required to be disclosed by the Company in reports that we file is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Committee's rules and forms.

(b) Changes in internal controls.

There were no significant changes in our internal controls or in other factors that could significantly affect these controls subsequent to the date of their evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Item 8B. Other Information

None.

PART III

Item 9. Directors and Executive Officers of the Registrant

Code of Business Conduct and Ethics

We have a Code of Business Conduct and Ethics that applies to all directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer. You can find our Code of Business and Ethics on our website by going to the following address: www.astralisltd.com. We will post any amendments to the Business Code of Conduct and Ethics as well as any waivers that are required to be disclosed by the rules of the Securities and Exchange Commission on our website.

Our Board of Directors has adopted Corporate Governance Guidelines and Charters for the Audit, Compensation and Nominating and Corporate Governance Committees of the Board of Directors. You can find these documents on our website by going to the following address: www.astralisltd.com.

Edgar Filing: ASTRALIS LTD - Form 10KSB

You can also obtain a printed copy of any of the materials referred to above by contacting us at the following address: 75 Passaic Avenue, Fairfield, New Jersey 07004, Attention: Secretary.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires our executive officers and directors and persons who own more than 10% of our common stock ("Reporting Persons") to file reports of ownership and changes in ownership of our common stock with the SEC. Reporting Persons are required by SEC regulations to furnish us with copies of all reports they file pursuant to Section 16(a).

Based solely on our review of the copies of such forms received or written representations from Reporting Persons, we believe that with respect to the fiscal year ended December 31, 2005, all the Reporting Persons complied with all applicable filing requirements except that Fabien Pictet failed to timely file Forms 4 and Forms 5.

Directors and Executive Officers

The names, ages and positions of our current directors and executive officers are as follows:

27

Name	Age	Position
Jose Antonio O'Daly, M.D., Ph.D.	64	Chairman of the Board of Directors and Chief Scientific Officer
Michael Garone	47	Chief Financial Officer, Interim Chief Executive Officer and Interim President
Michael Ashton	60	Director
Samuel Barnett, Ed.D.	58	Director
Fabien Pictet	47	Director
Gordon Schooley, Ph.D.	59	Director
Manuel Tarabay	53	Director

There are no familial relationships among our directors and/or officers. Directors hold office until the next annual meeting of our stockholders or until their respective successors have been elected and qualified. Officers serve at the pleasure of the Board of Directors.

Jose Antonio O'Daly, M.D., Ph.D. Dr. O'Daly has served as our Chairman of the Board of Directors since November 2001, and was appointed our Chief Scientific Officer on December 22, 2004. From November 2001 to December 22, 2004, Dr. O'Daly served as our President of Research and Development. Dr. O'Daly is the sole founder of the Center for Research and Treatment for Psoriasis in Caracas, Venezuela and has served as its President since 1998. From 1972 to 1998, Dr. O'Daly served as Director and Head of Research of the Microbiology Center of the Venezuelan Institute of Scientific Investigations. Dr. O'Daly attended the Central University of Venezuela, Caracas, receiving his Doctorate of Medical Sciences in 1968. In 1971, Dr. O'Daly earned a Doctorate of Philosophy from the

Edgar Filing: ASTRALIS LTD - Form 10KSB

Johns Hopkins University in Baltimore, Maryland. Dr. O'Daly is an honorary member of the Venezuelan Medical Academy.

Michael Garone. Mr. Garone has served as our Chief Financial Officer since February 21, 2005. From October 13, 2004 to February 21, 2005, Mr. Garone served as our Interim Chief Financial Officer. During 2004, Mr. Garone founded Gar-1 Business Advisory Services, L.L.C., an independent consulting company for information movement and management companies. From 1983 to 2003, Mr. Garone was employed by AT&T, Inc. where he held various positions of increasing responsibilities, including Chief Financial Officer of AT&T Alascom and Financial Planning Vice President, Broadband and Internet Services. Mr. Garone began his career in finance as an Over-the-Counter stock trader specializing in high technology start-up companies. Mr. Garone holds a B.A. in Mathematics from Colgate University and an M.B.A. from Columbia University.

Michael Ashton. Mr. Ashton has served as one of our Directors since January 2002. Mr. Ashton has 30 years of experience in the pharmaceutical industry, and since 1997 he has held the position of Chief Executive Officer of SkyePharma PLC, a London-based drug delivery technology provider. Prior to joining SkyePharma, Mr. Ashton served as Chairman and Chief Executive Officer of the U.S. subsidiary of Faulding, Australia's largest pharmaceutical companies. Mr. Ashton is a member of the Board of Directors of Transition Inc. Mr. Ashton holds a Bachelor of Pharmacy Degree from Sydney University and an M.B.A. from Rutgers University.

28

Samuel Barnett, Ed.D. Mr. Barnett has served as one of our Directors and a member of our audit committee since June 2004. In 1979, Mr. Barnett founded Barnett International, a consulting firm, and served as Chief Consultant from 1979 to 1999. From 1999 to 2000, Mr. Barnett served as Lead Partner of the Americas Pharmaceutical Practice of PricewaterhouseCoopers Consulting. From 2000 to 2005, he served as Lead Partner of the Americas Life Sciences Consulting Practice for IBM Business Consulting Services. Mr. Barnett holds a Bachelor's Degree from Wesleyan University and received both his Master's and Doctorate Degrees from Temple University.

Fabien Pictet. Mr. Pictet has served as one of our Directors since February 2002. Since 1998, Mr. Pictet has served as Chairman of Fabien Pictet and Partners, a London-based investment firm. Mr. Pictet has 20 years of experience in investing in emerging markets. During his 11 year tenure with Pictet and Cie, from 1986 to 1997, Mr. Pictet held various positions ranging from Manager responsible for U.S. equity investments to Partner responsible for all of the firm's institutional activities in Geneva, Zurich and London. Mr. Pictet holds a Bachelor's Degree in Economics from the University of San Francisco and a Master's Degree in International Management from American Graduate School of International Management. On April 19, 2006, Mr. Pictet announced that he will be resigning as a member of the Board of Directors. However, an effective date of Mr. Pictet's resignation has not yet been set.

Gordon Schooley, Ph.D. Dr. Schooley has served as one of our Directors and a member of our Medical Advisory Board since April 11, 2005. Dr. Schooley has over 33 years of experience in the pharmaceutical field, including extensive experience in clinical and product development. Since 1999, Dr. Schooley has served as Chief Scientific Officer of SkyePharma PLC. From 1989 to 1998, Dr. Schooley served as Vice President of Clinical and Regulatory Affairs for Alliance Pharmaceutical Corp. From 1987 to 1989, Dr. Schooley served as Vice President of Clinical and Regulatory Affairs for Newport Pharmaceuticals International, Inc. From 1979 to 1987, Dr. Schooley served as Director of Clinical Research, Biostatistics and Computing Services for Allergan

Edgar Filing: ASTRALIS LTD - Form 10KSB

Pharmaceuticals. Dr. Schooley currently serves as a member of the Scientific Advisory Boards of Topigen Pharmaceuticals, Inc., Progen Ltd., and Seacology Foundation. Dr. Schooley holds a B.S. and an M.S. in Business and Statistics from Brigham Young University and received his Doctorate of Philosophy in Biostatistics from the University of Michigan School of Public Health.

Manuel Tarabay. Mr Tarabay has served as one of our Directors since August 19, 2005. Mr. Tarabay joined the Board in connection with the investment of \$2 million by Blue Cedar. He serves as Blue Cedar's representative on the Board in accordance with the terms of Blue Cedar's investment which closed on August 19, 2005. Mr. Tarabay also acts as financial advisor to several investors who reside in the Middle East and Europe. During his 25 year career in Finance he has had various assignments throughout the world with Merrill Lynch, JPMorgan, Bankers Trust, Donaldson Lufkin Jenrette, and Credit Suisse First Boston. Mr. Tarabay holds a B. A. Degree in Mathematics (Computer Sciences) from Dartmouth College; a M. S. Degree in Computer Electronics Engineering from the Jesuit School of Engineering in Beirut; and an MBA Degree in Finance from Insead in Fountainbleau.

29

Advisors

Medical Advisory Board

James Leyden, M.D. Dr. Leyden has served as the Chairman of our Medical Advisory Board since November 2001. Dr. Leyden has been a Professor of Dermatology at the Hospital of the University of Pennsylvania in Philadelphia since 1983. He has served on the boards of many of the nation's key dermatological committees, including those of the American Academy of Dermatology and the Dermatology Foundation. Dr. Leyden has also served as a consultant to the U.S. Food and Drug Administration and the Federal Trade Commission, and to drug regulation agencies in England, Germany and Austria. Dr. Leyden has also assisted in the development, testing and commercialization of Accutane, Bactroban, Nizoral, Cleocin, Benzamycin, Benzaclin, Minocin and the use of bicarbonate to control body odor. Dr. Leyden holds a Bachelor's Degree from Saint Joseph's College and an M.D. from the University of Pennsylvania School of Medicine.

Gerald Krueger, M.D. Dr. Krueger has served on our Medical Advisory Board since December 2003. Dr. Krueger is a Professor of Dermatology at the University of Utah School of Medicine. Dr. Krueger consults for the U.S. Food and Drug Administration on psoriasis and serves on the executive committee of the Dermatology Foundation. In addition, he recently completed a ten-year term as Chairman of the Medical Advisory Board of the National Psoriasis Foundation. Dr. Krueger has been elected into the Alpha Omega Honor Society of Medicine. He has received the Taub International Award for psoriasis research, the American Skin Association Award for psoriasis research and the National Psoriasis Foundation's Lifetime Achievement Award and Founders Award.

Our Medical Advisory Board does not hold any formal meetings. However, management consults with the Medical Advisory Board from time to time. On April 11, 2005, we also appointed Dr. Schooley to serve on our Medical Advisory Board.

Audit Committee

The Audit Committee of our Board of Directors is an "Audit Committee" for the purposes of Section 3(a) (58) of the Securities Exchange Act of 1934. The Audit Committee recommends to the Board of Directors the independent public accountants to be selected to audit our annual financial statements, evaluates internal accounting controls, reviews the adequacy of the internal audit budget,

Edgar Filing: ASTRALIS LTD - Form 10KSB

personnel and plan, and determines that all audits and exams required by law are performed fully, properly, and in a timely fashion. The sole member of the Audit Committee is Samuel Barnett. Currently, there is a vacancy on the Audit Committee as a result of Steven Fulda resigning on December 11, 2005 as a member of the Board of Directors and member of the Audit Committee. As a member of the Audit Committee, Mr. Fulda had served as the Audit Committee "financial expert" as defined by Item 401(e) of Regulation S-B of the Exchange Act. Samuel Barnett shall serve as the sole member of the Audit Committee until the Board of Directors appoints a member of the Board of Directors to fill the vacancy on the Audit Committee left by Mr. Fulda's resignation.

Other than in his capacity as a member of the Audit Committee, member of the Board of Directors or a member of any of our other Board committees, Mr. Barnett has not accepted from us, directly or indirectly, any consulting, advisory or other compensatory fee. In addition, Mr. Barnett does not have direct or indirect beneficial ownership of over 10% of our common stock or is one of our executive officers. Our Board of Directors has determined that Mr. Barnett is "independent" under NASD Rule 4200 and Item 7(d)(3)(iv) of Schedule 14A, promulgated under the Exchange Act.

30

Item 10. Executive Compensation.

The following table sets forth certain information regarding compensation paid by us and our predecessors during each of the last three fiscal years to our Chief Executive Officer and any other executive officer who received compensation greater than \$100,000 during any of the last three fiscal years.

Summary Compensation Table

Name and Principal Position -----	Year ----	Annual Compensation	
		Salary (\$) -----	Other Annual Compensation (\$) -----
James Sharpe Former President and Chief Executive Officer (1)	2005	231,000	
	2004	--	--
	2003	--	--
	2002	--	--
Mike Ajnsztajn Prior Chief Executive Officer (2)	2004	109,875	2,437(4)
	2003	154,375	4,613
	2002	150,000	4,613
Jose Antonio O'Daly, Chairman of the Board of Directors and Chief Scientific Officer (3)	2005	217,482	34,283(6)
	2004	188,487	41,004(5)
	2003	158,750	73,740
	2002	150,000	56,671
Michael Garone (7) Chief Financial Officer, interim Chief Executive Officer and interim President	2005	187,200	--

(1) On January 25, 2006, we accepted the resignation of Mr. Sharpe, effective December 31, 2005 with respect to his position as a member of our Board of Directors and with respect to his position as our Chief Executive Officer and President.

Edgar Filing: ASTRALIS LTD - Form 10KSB

(2) On July 28, 2004, we accepted the resignation of Mr. Ajnsztajn, effective immediately with respect to his position as a member of our Board of Directors and effective August 26, 2004 with respect to his position as our Chief Executive Officer.

(3) Dr. O'Daly became one of our employees on July 1, 2002. Prior to July 1, 2002, Dr. O'Daly provided services as a consultant to the company.

(4) For the fiscal year ended December 31, 2004, this amount includes \$2,437 in health insurance premiums paid by us for Mr. Ajnsztajn's benefit.

31

(5) For the fiscal year ended December 31, 2004, this amount includes \$8,707 in health insurance premiums paid by us for Dr. O'Daly's benefit, an automobile allowance of \$5,729 and \$26,568 for a furnished apartment.

(6) For fiscal year ended December 31, 2005, this amount includes legal fees paid by the Company for Dr. O'Daly's benefit in accordance with his employment contract.

(7) Mr. Garone became the Chief Financial Officer as of February 21, 2005. As of January 25, 2006, Mr. Garone was appointed by the Board of Directors to serve as interim Chief Executive Officer and interim President until the Board elects a new Chief Executive Officer and President to replace James Sharpe.

Employment Agreements

On December 22, 2004, we entered into an employment agreement with Jose Antonio O'Daly, the Chairman of our Board of Directors and our Chief Scientific Officer. Under the terms of his employment agreement, Dr. O'Daly is entitled to an annual base salary of \$231,000 payable in arrears in bi-monthly installments, less statutory deductions (the "Base Salary") and an annual bonus of up to 25% of his Base Salary and based upon achievement of such goals and subject to such additional terms as may be determined by the Board of Directors. As a member of our senior management team, Dr. O'Daly has been granted the option to purchase 728,000 shares of our common stock with an initial exercise price of \$0.70 per share. The options are fully vested and have a term of ten years. In the event of a voluntary termination for "good reason" or if Dr. O'Daly is terminated following a change in control or without "cause," he generally will receive, among other things, the following severance benefits: (a) an amount equal to two times his annual Base Salary established for the fiscal year in which the date of termination occurs and (b) an amount equal to two times his annual bonus award established for the fiscal year in which his date of termination occurs. In the event of a voluntary termination by Dr. O'Daly without good reason, or if Dr. O'Daly is terminated by us for cause, he will receive the following severance benefits: (a) an amount equal to his Base Salary for one year and (b) an amount equal to one times his annual bonus award established for the fiscal year in which his date of termination occurs. The employment agreement includes certain non-competition and confidentiality provisions.

On January 27, 2005, we entered into an employment agreement with James Sharpe, our former Chief Executive Officer and President, pursuant to which Mr. Sharpe was entitled to (i) an annual base salary of \$231,000 payable in arrears in bi-monthly installments, less statutory deductions ("Sharpe's Base Salary"); (ii) an annual bonus of up to 25% of Sharpe's Base Salary, based upon achievement of such goals and subject to such additional terms as were to be determined by the Board of Directors; and (iii) 100,000 shares of fully vested common stock issued on Mr. Sharpe's first day of employment. In addition, in

Edgar Filing: ASTRALIS LTD - Form 10KSB

accordance with his employment agreement, Mr. Sharpe had been granted options to purchase 728,000 shares of common stock, of which options to purchase 182,000 shares had vested at the time of his resignation. Mr. Sharpe resigned from his positions at the Company, pursuant to the terms of the Separation Agreement, dated January 25, 2006. Pursuant to the terms of the Separation Agreement, Mr. Sharpe received a severance payment in the amount of \$50,000. In addition, in accordance with the terms of the Separation Agreement, Mr. Sharpe had been granted options to purchase 182,000 shares of common stock which vested on January 27, 2006 at the market price as of such date and additional options to purchase 182,000 shares of common stock on January 27, 2007 at the market price as of such date.

On February 21, 2005, we entered into a consultant agreement with Michael Garone, whereby Mr. Garone was retained on a full-time, exclusive basis to serve as our Chief Financial Officer (the "Consultant Agreement"). As Chief Financial Officer, Mr. Garone is responsible for, among other things, our financial planning and funding. In addition, Mr. Garone leads and implements our long-term

32

strategy and vision to provide successful growth in value for our investors and shareholders. Under the terms of the Consultant Agreement, Mr. Garone is entitled to a monthly fee of at least \$15,600. We have agreed to indemnify Mr. Garone against any claims that may arise as a result of the performance of his duties as our Chief Financial Officer under the consultant agreement and to include him, at our cost, as an insured party under our current directors' and officer' liability insurance policy. The term of the consultant agreement will continue until terminated by either party without cause upon 30 days written notice or with cause upon 10 days written notice.

On January 25, 2006 the Company's Board of Directors appointed Mr. Garone to serve as interim Chief Executive Officer and interim President until the Company's Board of Directors elects a new Chief Executive Officer and President to replace Mr. Sharpe.

None of our other executive officers receive compensation pursuant to any standard arrangement for their services as executive officers.

2001 Stock Option Plan

Our 2001 Stock Option Plan ("2001 Plan") was unanimously adopted by the Board of Directors on November 1, 2001 and approved by our stockholders at a special meeting held on November 1, 2001. The 2001 Plan provides for the issuance of 5,000,000 shares of common stock underlying stock options available for grant thereunder. The purpose of the 2001 Plan is to provide additional incentive to our directors, officers, employees and consultants who are primarily responsible for our management and growth. Each option will be designated at the time of grant as either an incentive stock option (an "ISO") or as a non-qualified stock option (a "NQSO"). As of December 31, 2005, options to purchase 1,454,000 shares of common stock have been granted under the 2001 Plan.

The 2001 Plan will be administered by our Board of Directors, or by any committee that we may in the future form and to which the Board of Directors may delegate the authority to perform such functions (in either case, the "Administrator").

Every person who at the date of grant of an option is an employee of ours or any affiliate of ours is eligible to receive NQSOs or ISOs under the 2001 Plan. Every person who at the date of grant is a consultant to, or non-employee

Edgar Filing: ASTRALIS LTD - Form 10KSB

director of, ours or any affiliate of ours is eligible to receive NQSOs under the 2001 Plan.

The exercise price of a NQSO will be not less than 85% of the fair market value of the stock subject to the option on the date of grant. To the extent required by applicable laws, rules and regulations, the exercise price of a NQSO granted to any person who owns, directly or by attribution under the Code (currently Section 424(d)), stock possessing more than 10% of the total combined voting power of all classes of our stock or stock of any of our affiliates (a "10% Shareholder") will not be less than 110% of the fair market value of the stock covered by the option at the time the option is granted. The exercise price of an ISO will be determined in accordance with the applicable provisions of the Code and will not be less than the fair market value of the stock covered by the option at the time the option is granted. The exercise price of an ISO granted to any 10% Shareholder will not be less than 110% of the fair market value of the stock covered by the option at the time the option is granted.

The Administrator, in its sole discretion, will fix the term of each option, provided that the maximum term of an option will be ten years. ISOs granted to a 10% Shareholder will expire not more than five years after the date of grant. The 2001 Plan provides for the earlier expiration of options in the event of certain terminations of employment of the holder.

33

Options may be granted and exercised under the 2001 Plan only after there has been compliance with all applicable federal and state securities laws. The 2001 Plan will terminate within ten years from the date of its adoption by the Board of Directors.

If for any reason other than death or permanent and total disability, an optionee ceases to be employed by us or any of our affiliates (such event being called a "Termination"), options held at the date of Termination (to the extent then exercisable) may be exercised in whole or in part at any time within three months of the date of such Termination, or such other period of not less than thirty days after the date of such Termination as is specified in the Option Agreement or by amendment thereof (but in no event after the expiration date of the option (the "Expiration Date")); provided, however, that if such exercise of the option would result in liability for the optionee under Section 16(b) of the Exchange Act, then such three-month period automatically will be extended until the tenth day following the last date upon which optionee has any liability under Section 16(b) (but in no event after the Expiration Date).

The Board of Directors may at any time amend, alter, suspend or discontinue the 2001 Plan. Without the consent of an optionee, no amendment, alteration, suspension or discontinuance may adversely affect outstanding options except to conform the 2001 Plan and ISOs granted under the 2001 Plan to the requirements of federal or other tax laws relating to ISOs. No amendment, alteration, suspension or discontinuance will require shareholder approval unless (i) shareholder approval is required to preserve incentive stock option treatment for federal income tax purposes or (ii) the Board of Directors otherwise concludes that shareholder approval is advisable.

Board Composition

We currently have six directors, each serving a term until the next annual meeting of stockholders. Pursuant to the Blue Cedar Stockholder's Agreement, Blue Cedar may designate one director to our Board of Directors. Manuel Tarabay is Blue Cedar's initial and current designated director. The Blue Cedar Stockholder's Agreement will terminate upon the later of the Blue Cedar

Edgar Filing: ASTRALIS LTD - Form 10KSB

Termination Date or August 15, 2008. The "Blue Cedar Termination Date" is the date on which Blue Cedar no longer beneficially owns, in the aggregate, at least 20% of the outstanding common stock of the Company. Further, pursuant to the Amended SkyePharma Stockholders' Agreement, our Board of Directors must include at least two independent directors and SkyePharma has the right to nominate one director. Michael Ashton is SkyePharma's initial and current nominated director. Until January 20, 2007, Dr. O'Daly has the right to nominate one director. The Amended SkyePharma Stockholders' Agreement will terminate upon the later of (i) the date on which SkyePharma no longer beneficially owns, in the aggregate, at least 20% of our outstanding common stock or (ii) January 20, 2007. Further, the Amended SkyePharma Stockholders' Agreement may be terminated by the mutual written consent of the parties.

Compensation of Directors

We reimburse all outside directors for travel and lodging expenses related to scheduled board meetings. Our Board of Directors authorized the following payments for non-executive directors during the fiscal year-ended December 31, 2005: \$1,000 for each board meeting attended in person and \$400 for each meeting attended by teleconference; an annual retainer of \$4,000 paid to the Chairman of the Audit Committee; \$1,000 paid to each Audit Committee member per financial filing; an annual retainer of \$2,500 paid to the Chairman of the Compensation Committee; an annual retainer of \$1,500 paid to each Compensation Committee member, other than the Chairman; an annual retainer of \$3,000 paid to the Chairman of the Strategic Planning Committee; an annual retainer of \$1,000 paid to each Strategic Planning Committee member, other than the Chairman; and \$1,000 paid to each Strategic Planning Committee member for each half-day strategic planning meeting attended in person. In addition, each non-executive Director will receive a one-time grant upon election to the Board of stock options to purchase 50,000 shares of our common stock, vesting over a four-year period with the first 25% vesting on the date of grant, and an annual grant upon the anniversary of election to the Board of stock options to purchase 20,000 shares of our common stock, vesting over a four-year period with the first 25% vesting on the date of grant. Other than the foregoing, our directors do not receive compensation pursuant to any standard arrangement for their services as directors.

34

Indemnification Matters

Our Certificate of Incorporation eliminates the personal liability of directors to the fullest extent permitted by the provisions of paragraph (7) of subsection (b) of Section 102 of the General Corporation Law of Delaware. In addition, our Certificate of Incorporation includes provisions to indemnify our officers and directors and other persons against expenses, judgments, fines and amounts paid in settlement in connection with threatened, pending or completed suits or proceedings against those persons by reason of serving or having served as officers, directors or in other capacities to the fullest extent permitted by Section 145 of the General Corporation Law of Delaware.

Our bylaws provide the power to indemnify our officers, directors, employees and agents or any person serving at our request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise to the fullest extent permitted by Delaware law.

Item 11. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table sets forth the names and beneficial ownership of our

Edgar Filing: ASTRALIS LTD - Form 10KSB

common stock owned as of March 31, 2006, by (i) each of our directors, (ii) each person named in the Summary Compensation Table, (iii) all our directors and executive officers as a group, and, to the best of our knowledge, (iv) all holders of 5% or more of the outstanding shares of our common stock. Unless otherwise noted, the address of all the individuals and entities named below is care of Astralis Ltd. at 75 Passaic Avenue, Fairfield, NJ 07004.

Name and Address	Number of Shares of Common Stock Beneficially Owned (1)	Percentage of Common Stock Owned
Dr. Jose Antonio O'Daly (2) (3)	14,368,000	15.6%
Michael Ashton (4)	36,413,900	39.8%
Samuel Barnett, Ph.D (5)	130,000	*
Fabien Pictet (6)	3,677,794	3.9%
Gordon Schooley (7)	12,500	*
Manuel Tarabay (8)	880,500	*
Blue Cedar (9) P.O. Box 546 28-30 The Parade St. Helier, Jersey JE4 8X9 Channel Islands, United Kingdom	54,040,404	42.4%
SkyePharma (3) (4) 105 Piccadilly London W1J 7NJ England	36,413,900	39.8%
All Officers and Directors as a Group (2) (4) (5) (6) (7) (8)	109,523,098	84.3%

* Less than 1%

(1) Beneficial ownership is determined in accordance with Rule 13d-3(a) of the Securities Exchange Act of 1934 and generally includes voting or investment power with respect to securities. Except as indicated by footnotes and subject to community property laws, where applicable, the person named above has sole voting and investment power with respect to all shares of the common stock shown as beneficially owned by him. The beneficial ownership percentage is based on 91,454,873 shares of our common stock outstanding as of March 31, 2006.

(2) Includes 13,640,000 shares of common stock and vested options to purchase 728,000 shares of common stock.

(3) Under the terms of Amended SkyePhama Stockholders' Agreement dated as of January 20, 2004 by and among us, SkyePharma, Dr. O'Daly and our other original

Edgar Filing: ASTRALIS LTD - Form 10KSB

shareholders, the parties agreed to vote all shares held by such parties for (i) one director designated by SkyePharma, (ii) one director designated by Dr. O'Daly, (iii) one director designated by each of the other three original shareholders and (iv) two independent director. No party to the agreement has the right to dispose (or direct the disposition of) any shares of common stock held by any of the other parties to the agreement. Accordingly, each party disclaims beneficial ownership of the shares held by the other parties. Since the date of such agreement, the other three original shareholders resigned their positions with us and transferred all of their shares of common stock to SkyePharma. As a result, none of them have any rights to designate a director under the Agreement

(4) Includes 36,393,900 shares of common stock beneficially owned by SkyePharma and warrants to purchase 20,000 shares of common stock beneficially owned by SkyePharma that are exercisable within 60 days of March 31, 2006. Mr. Ashton is Chief Executive Officer of SkyePharma. Under the terms of a Call Option Agreement dated January 20, 2004, we have the right to repurchase some or all of 12,500,000 shares of our common stock from SkyePharma. In June 2004, we assigned the right to purchase 1,250,000 shares under the Call Option Agreement to FPP Capital Advisors, an entity controlled by Fabien Pictet. The call option will be exercisable by us for a period commencing upon our achievement of a certain milestone event and ending on January 20, 2007.

(5) Includes 100,000 shares of common stock and options to purchase 30,000 shares of common stock that are exercisable within 60 days of March 31, 2006.

36

(6) Includes 1,260,000 shares of common stock owned by FPP Emerging Hedge Fund 1, Ltd. and warrants to purchase an aggregate of 632,000 shares of common stock owned by FPP Emerging Hedge Fund 1, Ltd. that are exercisable within 60 days of March 31, 2006. Includes 390,000 shares of common stock and warrants to purchase 500,000 shares of common stock owned by Perly International Ltd. that are exercisable within 60 days of March 31, 2006. Includes 180,000 shares of common stock owned by Pictet Private Equity Investors, S.A. and warrants to purchase 36,000 shares held by Pictet Private Equity Investors S.A. that are exercisable within 60 days of March 31, 2006. Includes 150,000 shares of common stock owned by FPP Capital Advisors and warrants to purchase 519,794 shares held by FPP Capital Advisors that are exercisable within 60 days of March 31, 2006. Mr. Pictet controls FPP Emerging Hedge Fund 1, Ltd., Perly International Ltd., Pictet Private Equity Investors, S.A., and FPP Capital Advisors. In June 2004, we assigned the right to purchase 1,250,000 shares of our common stock under the Call Option Agreement between us and SkyePharma to FPP Capital Advisors, an entity controlled by Fabien Pictet. The shares beneficially owned by Mr. Pictet, as reflected in this table do not include these 1,250,000 shares. On April 19, 2006, Mr. Pictet announced that he will be resigning from the Board of Directors. However, an effective date of Mr. Pictet's resignation has not yet been set.

(7) Includes options to purchase 12,500 shares of common stock that are exercisable within 60 days of March 31, 2006.

(8) Includes 796,000 shares of common stock, warrants to purchase 72,000 shares of common stock within 60 days of March 31, 2006 and options to purchases 12,500 shares of common stock within 60 days of March 31, 2006. Mr. Tarabay is the Blue Cedar designee to the Board of Directors.

(9) Includes 18,181,818 shares of common stock owned by Blue Cedar and (i) warrants to purchase 18,181,818 shares of common stock for a period of five years and (ii) warrants to purchase 12,121,212 shares of common stock for a

Edgar Filing: ASTRALIS LTD - Form 10KSB

period of twelve months. The warrants may be exercised as of August 17, 2005. Includes a promissory note that is convertible into 2,777,778 common stock and warrants to purchase 2,777,778 common stock for a period of five years.

Item 12. Certain Relationships and Related Transactions

Relationship with Dr. Jose Antonio O'Daly

In January 2004 the PTO issued a patent to Dr. Jose O'Daly for the "Compositions and Methods for the Treatment and Clinical Remission of Psoriasis" (the "Psoriasis Formula"). Under the terms of a license agreement and assignment of license agreement, we have the exclusive right and license to use and exploit this patent. Dr. O'Daly will continue to maintain ownership rights with respect to the patent and patent application. However, Dr. O'Daly has granted us a perpetual, royalty free license to his patent under the agreements, which will terminate only upon the expiration of the patent, or upon the commencement of a bankruptcy or insolvency proceeding involving our company or upon our dissolution or liquidation.

In March 2002, Akiva LLC, an entity controlled by Dr. O'Daly, also filed an application to obtain patent protection internationally for the Psoriasis Formula under the Patent Cooperation Treaty. In addition, in August 2003, Akiva LLC filed patent applications in the European Union, Australia, Brazil, Canada, Mexico and Japan. We have rights to these applications, which are currently pending, pursuant to the license and assignment of license agreements described above.

37

In January 2004, Dr. O'Daly filed a patent application with the PTO focusing primarily on the mechanism of action of our initial injectable product candidate, Psoraxine(R), expanding the claims to include medical indications other than psoriasis, such as Atopic Dermatitis, Psoriatic Arthritis and Rheumatoid Arthritis. In January 2004, Dr. O'Daly also filed a second patent relating to a culture medium for parasitic organisms, which is part of our technology platform. Dr. O'Daly has assigned to us the rights in these patent applications.

Relationship with SkyePharma

We entered into a Purchase Agreement dated as of December 10, 2001 with SkyePharma pursuant to which SkyePharma purchased an aggregate of 2,000,000 shares of our Series A Preferred Stock, for an aggregate purchase price of \$20.0 million. On January 20, 2004, pursuant to the Omnibus Conversion Agreement dated January 12, 2004 between us and SkyePharma, SkyePharma converted all of its 2,000,000 shares of Series A Preferred Stock into 25,000,000 shares of our common stock at a conversion price of \$0.80 per share. On March 3, 2005, SkyePharma acquired 11,160,000 additional shares of our common stock in a privately negotiated transaction. As a result, as of April 29, 2005 SkyePharma beneficially owns 49.8% of our common stock on a fully diluted basis.

On January 20, 2004, in connection with SkyePharma's conversion of our Series A Preferred Stock, we entered into the Call Option Agreement with SkyePharma, pursuant to which we received the right to repurchase some or all of 12,500,000 shares of our common stock from SkyePharma at a premium to the \$0.80 conversion price. In the event we exercise the call option, the exercise price will be between \$1.28 and \$1.52 per share, depending on the date of exercise. The call option will be exercisable by us upon our achievement of a certain milestone event and ending on January 20, 2007.

Edgar Filing: ASTRALIS LTD - Form 10KSB

On January 20, 2004, we, SkyePharma, Dr. O'Daly and our other original shareholders entered into the Amended SkyePharma Stockholders' Agreement. Pursuant to the Amended SkyePharma Stockholders' Agreement, our Board of Directors is required to be comprised of at least seven Directors and must include at least two independent Directors. Per the Amended SkyePharma Stockholders' Agreement, SkyePharma has the right to nominate one Director. Michael Ashton is SkyePharma's initial and current nominated Director. Until January 20, 2007, Dr. O'Daly has the right to nominate one Director. The Amended SkyePharma Stockholders' Agreement will terminate upon the later of (i) the date on which SkyePharma no longer beneficially owns, in the aggregate, at least 20% of our outstanding common stock or (ii) January 20, 2007. Further, the Amended SkyePharma Stockholders' Agreement may be terminated by the mutual written consent of the parties. Pursuant to the Amended SkyePharma Stockholders' Agreement, SkyePharma is required to vote its shares of our common stock in favor of certain enumerated transactions, where those transactions have been approved by our Board of Directors and all of the independent Directors. These transactions include (i) the amendment of our certificate of incorporation solely to increase our authorized capital stock, (ii) the adoption or amendment of an employee benefit plan applicable to all employees, (iii) the issuance of additional securities for cash and (iv) the sale of all of our outstanding capital stock or all or substantially all of our assets, or our merger with another entity, provided that SkyePharma will receive the same consideration for its shares as other holders of common stock and will be able to participate in the sale or merger on the same terms as the most favorable terms available to any of our other stockholders and the total consideration for the transaction is greater than \$135 million.

38

We also entered into two agreements concerning the formulation and development of Psoraxine(R) with SkyePharma. Under the terms of the Technology Access Option Agreement, dated December 10, 2001, we paid to SkyePharma a \$5.0 million technology access fee for the option to acquire a license for certain drug delivery technologies owned by SkyePharma. Under the terms of the Technology Access Option Agreement, if we exercise our option, we must pay a royalty of 5% of net sales of all products manufactured or sold that use or exploit the drug delivery technologies that we license from SkyePharma. In addition, if we exercise our option, SkyePharma retains the right during the term of the Technology Access Option Agreement to undertake the manufacture of all of our products that incorporate or utilize the drug delivery technologies. The option we received under the Technology Access Option Agreement expires on December 10, 2008, unless terminated sooner pursuant to the terms of the Technology Access Option Agreement. Pursuant to the Technology Access Option Agreement, SkyePharma also has the right of first negotiation to acquire the worldwide marketing rights to Psoraxine(R).

On December 10, 2001, we entered into the Service Agreement with SkyePharma pursuant to which SkyePharma was to provide us with development, manufacturing, pre-clinical and clinical development services in consideration of \$11 million. The Service Agreement terminated on December 31, 2002. We entered into an Amendment to the Service Agreement with SkyePharma, effective as of January 1, 2003, to extend the term of the Service Agreement and modify the services to be provided by SkyePharma such that SkyePharma continued to provide certain services to us through December 31, 2004, in consideration for payments made during 2002. The agreement expired on December 31, 2004.

Relationship with FPP Capital Advisors

In connection with private placements of units consisting of common stock and warrants that occurred in 2004, FPP Advisors, an entity controlled by our

Edgar Filing: ASTRALIS LTD - Form 10KSB

board member, Fabien Pictet, received a consulting fee of \$261,496. In addition, for consulting services provided in connection with the private placement, FPP Advisors and certain other selling stockholders received warrants to purchase an aggregate of 418,394 shares of our common stock at \$0.50 per share and warrants to purchase an aggregate of 418,394 shares of our common stock at \$0.73 per share. Upon exercise of the warrants issued in the private placement, we will pay a cash commission equal to 5% of the amounts raised through the exercise of the warrants.

In addition, in consideration for services provided in negotiating our Omnibus Conversion Agreement with SkyePharma, we issued to FPP Capital Advisors units consisting of 150,000 shares of common stock and warrant stock and warrants to purchase 150,000 shares of common stock at an exercise price of \$0.73 per share. We also assigned the right to purchase 1,250,000 shares under our Call Option Agreement with SkyePharma to FPP Capital Advisors.

In addition to FPP Capital Advisors, Fabien Pictet controls FPP Emerging Hedge Fund I and Pictet & Cie, both of which were investors in our private placements in early 2004.

Relationship with Blue Cedar and Lipworth Capital Limited

On March 31, 2006, the Company closed a private placement of securities from which it received proceeds of \$250,000. In connection with such private placement, the Company issued to Blue Cedar, an accredited investor and currently a stockholder of the Company, (i) a convertible promissory note in the principal amount of \$250,000, convertible into shares of the Company's Common Stock at \$0.09 per share, and (ii) a warrant to purchase 2,777,778 shares of Common Stock. Lipworth Capital Limited acted as the placement agent in connection with this private placement. The securities offered and sold in this private placement were sold in reliance on an exemption from the registration requirements under Regulation D of the Securities Act of 1933.

39

Additionally, on August 19, 2005, we completed a private placement of securities from which we received gross proceeds of approximately \$2,000,000. The transaction consisted of the sale to one accredited investor, Blue Cedar, of units consisting of: (i) 18,181,818 shares of common stock, (ii) warrants to purchase over a 5-year period 18,181,818 shares of common stock with an exercise price of \$0.165 and (iii) warrants to purchase over a 12-month period 12,121,212 shares of common stock with an exercise price of \$0.165. We relied upon the exemption from registration provided under Section 4(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder. The private placement was only made available to one "accredited investor" as defined in Rule 501 of Regulation D. Lipworth Capital Limited acted as our placement agent in connection with the private placement. We paid an 8% fee to our placement agent and issued warrants to purchase 1,454,545 shares of common stock with an exercise price of \$0.165, in connection with the financing in addition to other costs. Additionally, we granted Blue Cedar certain registration rights pursuant to a registration rights agreement, dated as of August 17, 2005, in connection with this transaction. The registration rights agreement required us to file a registration statement within approximately 30 days of the final closing of our private placement covering the resale of all shares included therein, as well as the shares underlying the warrants. Because a registration statement covering the resale of such shares was not filed or effective by December 31, 2005, the date specified in the agreement, we are subject to liquidated damages payments of \$10,000 per month, being 0.5% of the aggregate purchase price plus 10% interest per annum to be paid on unpaid liquidated damages amounts until such time as a registration statement covering the resale of securities sold to Blue

Edgar Filing: ASTRALIS LTD - Form 10KSB

Cedar is declared effective by the Securities and Exchange Commission.

Concurrently with the closing of the private placement, we and Blue Cedar entered into the Blue Cedar Stockholder's Agreement. Pursuant to the Blue Cedar Stockholder's Agreement, our Board of Directors is required to be comprised of at least eight directors and Blue Cedar may designate one director to the Board of Directors of the Company. Manuel Tarabay is Blue Cedar's initial and current designated director. Further, pursuant to the Blue Cedar Stockholder's Agreement, we agreed not to enter into any service agreement, distribution arrangement or transfer of personnel with any of our stockholders owning more than 10% of the outstanding shares of common stock until we complete Phase II clinical trials of Psoraxine(R), without the prior written consent of Blue Cedar, which shall not be unreasonably withheld. Additionally, for a period of two years following the closing date of the private placement, we granted Blue Cedar certain pre-emptive rights, allowing Blue Cedar to participate in substantially all sales of securities. The Blue Cedar Stockholder's Agreement will terminate upon the later of the Blue Cedar Termination Date or August 15, 2008. The "Blue Cedar Termination Date" is the date on which Blue Cedar no longer beneficially owns, in the aggregate, at least 20% of our outstanding common stock.

Item 13. Exhibits

Exhibit Number	Description
-----	-----
3.1 (1)	Certificate of Incorporation of Astralis Ltd.
3.2 (2)	Bylaws of Astralis Ltd.
4.1 (9)	Specimen Stock Certificate
10.1 (2)	Agreement and Plan of Merger
10.2 (4)	Contribution Agreement dated September 10, 2001
10.3 (5)	Purchase Agreement dated December 10, 2001
10.4 (5)	Stockholder Agreement dated December 10, 2001
10.5 (7)	2001 Stock Option Plan
10.6 (3)	Sub-Lease Agreement
10.7 (3)	License Agreement dated April 26, 2001 between Jose Antonio O'Daly and Astralis LLC
10.8 (3)	Assignment of License
10.9 (3)	Form of Warrant
10.10 (8)	Agreement for Services dated December 10, 2001 between SkyePharma Inc. and Astralis Ltd.
10.11 (8)	Technology Access Option Agreement dated December 10, 2001 by and among SkyePharma Inc., SkyePharma Holding AG and Astralis Ltd.

Edgar Filing: ASTRALIS LTD - Form 10KSB

- 10.12 (6) Employment Agreement dated December 10, 2001, between Dr. Jose Antonio O'Daly and Astralis Ltd.
- 10.13 (6) Amendment #1 to Agreement for Services dated March 18, 2003 between SkyePharma Inc. and Astralis Ltd.
- 10.14 (7) Omnibus Conversion Agreement dated January 12, 2004 between Astralis Ltd. and SkyePharma PLC
- 10.15 (7) Call Option Agreement dated January 20, 2004 between Astralis Ltd. and SkyePharma PLC
- 10.16 (7) Amendment No. 1 to Stockholders Agreement dated January 20, 2004 by and among Astralis Ltd., SkyePharma PLC, Jose Antonio O'Daly, Mike Ajnsztajn, Gaston Liebhaber and Gina Tedesco
- 10.17 (11) Securities Purchase Agreement, dated August 17, 2005, by and between Astralis Ltd. and Blue Cedar Limited.
- 10.18 (11) Registration Rights Agreement, dated August 17, 2005, by and between Astralis Ltd. and Blue Cedar Limited.
- 10.19 (11) Stockholder's Agreement, dated August 17, 2005, by and between Astralis Ltd. and Blue Cedar Limited.
- 10.20 (11) Long-term Common Stock Purchase Warrant, issued to Blue Cedar Limited by Astralis Ltd.
- 10.21 (11) Short-term Common Stock Purchase Warrant, issued to Blue Cedar Limited by Astralis Ltd.
- 10.22 (11) Long-term Common Stock Purchase Warrant, issued to Lipworth Capital Limited by Astralis Ltd.
- 10.23 (12) Separation Agreement and General Release, dated January 25, by and between James Sharpe and the Registrant.
- 10.24 (13) Form of Subscription Agreement, dated March 31, 2006, by and between Astralis Ltd. and Blue Cedar Limited.
- 10.25 (13) Form of Warrant, dated March 31, 2006, issued to Blue Cedar Limited by Astralis Ltd.
- 10.26 (13) Form of Convertible Promissory Note in the principal amount of \$250,000, dated March 31, 2006, issued to Blue Cedar Limited by Astralis Ltd.
- 14.1 (1) Code of Ethics for Chief Executive Officer and Senior Financial Officers
- 31.1 Certification by the Interim Chief Executive Officer and the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32.1 Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

- (1) Previously filed with the Securities and Exchange Commission as an Exhibit to the Annual Report on Form 10-KSB on March 30, 2004.

- (2) Previously filed with the Securities and Exchange Commission as an Exhibit to the Preliminary Proxy Statement for Astralis Pharmaceuticals Ltd. on November 16, 2001.
- (3) Previously filed with the Securities and Exchange Commission as an Exhibit to the Registration Statement on Form SB-2 for Astralis Ltd. on March 14, 2002.
- (4) Previously filed with the Securities and Exchange Commission as an Exhibit to the Current Report on Form 8-K for Astralis Pharmaceuticals Ltd. on November 14, 2001.
- (5) Previously filed with the Securities and Exchange Commission as an Exhibit to the Current Report on Form 8-K for Astralis Ltd. on December 14, 2001.
- (6) Previously filed with the Securities and Exchange Commission as an Exhibit to the Annual Report on Form 10-KSB on March 31, 2003.
- (7) Previously filed with the Securities and Exchange Commission as an Exhibit to the Preliminary Proxy Statement for Hercules Development Group Inc. on October 4, 2001.
- (8) Previously filed with the Securities and Exchange Commission as an Exhibit to the Amendment to the Registration Statement on Form SB-2 for Astralis Ltd. on July 23, 2002.
- (9) Previously filed with the Securities and Exchange Commission as an Exhibit to the Registration Statement on Form SB-2 for Astralis Ltd. on May 28, 2004.
- (10) Previously filed with the Securities and Exchange Commission as an Exhibit to the Registration Statement on Form SB-2 for Astralis Ltd. on June 28, 2004.
- (11) Previously filed with the Securities and Exchange Commission as an Exhibit on Form 10-QSB on August 19, 2005.
- (12) Previously filed with the Securities and Exchange Commission as an Exhibit on Form 8-K on March 30, 2006.
- (13) Previously filed with the Securities and Exchange Commission as an Exhibit on Form 8-K on April 6, 2006.

Item 14. Principal Accountant Fees and Services

The following disclosure presents fees billed for professional services rendered by L J Soldinger Associates, LLC, our independent auditors, for 2005 and 2004.

Audit- Fees

The aggregate fees billed for professional services in connection with the audit of our annual financial statements, and the reviews of our quarterly financial statements and audit services provided in connection with regulatory filings, were approximately \$128,000 and \$168,000 for 2005 and 2004, respectively.

Edgar Filing: ASTRALIS LTD - Form 10KSB

Audit-Related Fees

42

The aggregate fees billed for assurance and related services in connection with securities registration and related matters were approximately \$24,000 and \$25,000 for 2005 and 2004, respectively.

Tax Fees

There were no tax related services provided by our independent auditors in 2005 or 2004.

All Other Fees

There were no other services provided by our independent auditors in 2005 or 2004.

Pre-Approval of Audit and Permissible Non-Audit Services

The Audit Committee pre-approves all audit and permissible non-audit services provided by the independent auditors. These services may include audit services, audit-related services, tax services and other services. The Audit Committee has adopted a policy for the pre-approval of services provided by the independent auditors. Under the policy, pre-approval is generally provided for up to one year and any pre-approval is detailed as to the particular service or category of services. In addition, the Audit Committee may pre-approve particular services on a case-by-case basis. All audit and permissible non-audit services provided by L J Soldinger Associates LLC to us for 2005 and 2004 were approved by the Audit Committee.

43

SIGNATURE PAGE

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ASTRALIS LTD

By: /s/ Michael Garone	April 21, 2006
-----	-----
Michael Garone	Date
Interim President, Interim Chief Executive Officer and Chief Financial Officer	
(Principal Executive Officer)	

Pursuant to the requirements the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By: /s/ Michael Garone	April 21, 2006
-----	-----
Michael Garone	Date
Interim President, Interim Chief Executive	

Edgar Filing: ASTRALIS LTD - Form 10KSB

Officer and Chief Financial Officer
(Principal Executive Officer, Principal
Financial and Accounting Officer)

By: /s/ Jose Antonio O'Daly

Jose Antonio O'Daly, M.D.
Chairman of the Board
and Chief Scientific Officer
April 21, 2006

Date

By: /s/ Michael Ashton

Michael Ashton
Director
April 21, 2006

Date

By: /s/ Samuel Barnett

Samuel Barnett
Director
April 21, 2006

Date

By: /s/ Fabien Pictet

Fabien Pictet
Director
April 21, 2006

Date

44

By: /s/ Manuel Tarabay

Manuel Tarabay
Director
April 21, 2006

Date

By: /s/ Gordon Schooley

Gordon Schooley, Ph.D.
Director
April 21, 2006

Date

45

Astralis, Ltd.
(A Development Stage Entity)
INDEX TO THE FINANCIAL STATEMENTS

	Page

Report of Independent Registered Public Accounting Firm	F2
Balance Sheets	F3
Statements of Operations	F4
Statements of Stockholders' Equity	F5

Edgar Filing: ASTRALIS LTD - Form 10KSB

Statements of Cash Flows	F11
Notes to Financial Statements	F12

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and
Stockholders of Astralis Ltd.

We have audited the accompanying balance sheets of Astralis Ltd. (a development stage entity) as of December 31, 2005 and 2004, and the related statements of operations, stockholders' equity and cash flows for the years then ended and the period March 12, 2001 (date of inception) through December 31, 2005. These financial statements are the responsibility of the company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Astralis Ltd. as of December 31, 2005 and 2004, and the results of its operations, changes in stockholders' equity and its cash flows for the years then ended and the period March 12, 2001 (date of inception) through December 31, 2005 in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has incurred net losses since inception, does not have sufficient funds to execute its business plan, and estimates its current cash will last through May 2006. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans regarding those matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

L J SOLDINGER ASSOCIATES, LLC

Deer Park, Illinois
April 3, 2006

Edgar Filing: ASTRALIS LTD - Form 10KSB

F-2

Astralis, LTD
(A Development Stage Entity)
BALANCE SHEETS

ASSETS

	December 31,	
	2005	2004
	-----	-----
Current Assets		
Cash and cash equivalents	\$ 633,468	\$ 2,312,
Prepaid expenses	64,207	70,
Supplies	32,108	55,
	-----	-----
Total Current Assets	729,783	2,439,
Other Intangible Assets, Net	--	117,
Property and Equipment, Net	101,371	214,
Deposits	25,000	26,
	-----	-----
	\$ 856,154	\$ 2,797,
	=====	=====
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current Liabilities		
Accounts payable and accrued expenses	\$ 475,102	\$ 397,
	-----	-----
Total Current Liabilities	475,102	397,
	-----	-----
Commitments and Contingencies		
Stockholders' Equity		
Common stock; \$.0001 par value; 150,000,000 shares authorized at 2005 and 2004; 91,454,873 and 73,173,055 issued and outstanding at 2005 and 2004	9,145	7,
Additional paid-in capital	53,988,423	52,095,
Deficit accumulated in the development stage	(53,616,516)	(49,702,
	-----	-----
Total Stockholders' Equity	381,052	2,400,
	-----	-----
	\$ 856,154	\$ 2,797,
	=====	=====

See the accompanying notes to financial statements

F-3

Edgar Filing: ASTRALIS LTD - Form 10KSB

Astralis, LTD
(A Development Stage Entity)
STATEMENTS OF OPERATIONS

	Year Ended December 31,		March
	2005	2004	(Incep Decem 2
Revenues	\$ --	\$ --	\$
Operating Expenses			
Research and development - related party	--	4,519,400	16,
Research and development	2,510,521	3,169,660	8,
Depreciation and amortization	25,345	30,403	
General and administrative	1,632,586	1,860,844	7,
Total Operating Expenses	4,168,452	9,580,307	32,
Loss From Operations	(4,168,452)	(9,580,307)	(32,
Other (income) expense			
Investment (income) loss	(30,372)	722	(
Registration rights penalty	83,000	--	
Total Other Expense (Income)	52,628	722	(
Loss before income tax benefit	(4,221,080)	(9,581,029)	(32,
Income tax benefit	306,921	293,461	
Net Loss	(3,914,159)	(9,287,568)	(31,
Preferred Stock Dividends	--	(10,750,000)	(22,
Net Loss to Common Stockholders	(3,914,159)	(20,037,568)	(53,
Basic and Diluted Loss per Common Share	\$ (0.05)	\$ (0.28)	\$
Basic and Diluted Weighted Average Common Shares Outstanding	79,985,782	71,073,507	51,

See the accompanying notes to financial statements

Edgar Filing: ASTRALIS LTD - Form 10KSB

ASTRALIS LTD.
(A Development Stage Entity)
Statements of Stockholders' Equity

	Preferred Stock		Common St
	Shares	Amount	Shares
Balances, March 12, 2001 (Date of Inception)	--	\$ --	--
Members' capital contributions, 3/15/2001	--	--	25,300,000
Capital contributions received, 3/1 - 8/13/2001	--	--	--
Members' contributed services, 3/15 - 6/30/2001	--	--	--
Members' capital contributions, 9/1/2001	--	--	2,700,000
Warrants to purchase 6,300,000 shares of common stock at \$1.60 per share issued in private placement	--	--	--
Common stock issuable for consulting services, 9/1/2001; 500,000 shares	--	--	--
Common stock issued in private placement net of issuance costs, 11/13/2001; 2,076,179 shares at \$1.60 per share	--	--	2,076,179
Warrants to purchase 415,237 shares of common stock at \$4.00 per share issued in private placement, 11/13/2001	--	--	--
Net assets and liabilities acquired in merger with Hercules	--	--	7,512,000
Preferred stock issued, net of issuance costs, 12/10/2001; 1,000,000 shares at \$10.00 per share	1,000,000	1,000	--
Preferred stock dividend, 12/10/2001	--	--	--
Options to purchase 200,000 shares of common stock at \$1.77 (based on valuation) issued for legal services, 12/31/2001	--	--	--
Options to purchase 100,000 shares of common stock at \$1.77 (based on valuation) issued for consulting services, 12/31/2001	--	--	--
Amortization of deferred compensation	--	--	--

Edgar Filing: ASTRALIS LTD - Form 10KSB

COMPREHENSIVE LOSS

Net loss	--	--	--
Total Comprehensive Loss	-----	-----	-----
Balance, December 31, 2001	1,000,000	\$ 1,000	37,588,179
	-----	-----	-----

See the accompanying notes to financial statements

F-5

ASTRALIS LTD.
(A Development Stage Entity)
Statements of Stockholders' Equity

	Subscription Receivable	Deferred Compensation	Accumulated Other Comprehensive Loss	Deficit Accumul During Develop Stag
	-----	-----	-----	-----
Balances, March 12, 2001 (Date of Inception)	\$ --	\$ --	\$ --	\$ --
Members' capital contributions, 3/15/2001	(33,183)	--	--	--
Capital contributions received, 3/1 - 8/13/2001	33,183	--	--	--
Members' contributed services, 3/15 - 6/30/2001	--	--	--	--
Members' capital contributions, 9/1/2001	(1,350,000)	--	--	--
Warrants to purchase 6,300,000 shares of common stock at \$1.60 per share issued in private placement	--	--	--	--
Common stock issuable for consulting services, 9/1/2001; 500,000 shares	--	--	--	--
Common stock issued in private placement net of issuance costs, 11/13/2001; 2,076,179 shares at \$1.60 per share	--	--	--	--
Warrants to purchase 415,237 shares of common stock at \$4.00 per share issued in private placement, 11/13/2001	--	--	--	--
Net assets and liabilities acquired in merger with Hercules	--	--	--	--
Preferred stock issued, net of issuance costs, 12/10/2001; 1,000,000 shares	--	--	--	--

Edgar Filing: ASTRALIS LTD - Form 10KSB

at \$10.00 per share	--	--	--	
Preferred stock dividend, 12/10/2001	--	--	--	(2,120)
Options to purchase 200,000 shares of common stock at \$1.77 (based on valuation) issued for legal services, 12/31/2001	--	(354,000)	--	
Options to purchase 100,000 shares of common stock at \$1.77 (based on valuation) issued for consulting services, 12/31/2001	--	(177,000)	--	
Amortization of deferred compensation	--	132,750	--	
COMPREHENSIVE LOSS				
Net loss				(4,075)

Total Comprehensive Loss				
Balance, December 31, 2001	\$ (1,350,000)	\$ (398,250)	\$ --	\$ (6,195)
	-----	-----	-----	-----

See the accompanying notes to financial statements

F-6

ASTRALIS LTD.
(A Development Stage Entity)
Statements of Stockholders' Equity

	Preferred Stock		Common
	Shares	Amount	Shares
	-----	-----	-----
Balances Brought Forward	1,000,000	\$ 1,000	37,588,179
Oversubscription of common stock issued in private placement, 11/13/2001; 49,990 shares cancelled at \$1.60 per share, 1/24/2002	--	--	(49,990)
Preferred stock issue, net of issuance costs, 1/31/2002; 250,000 shares at \$10.00 per share	250,000	250	--
Preferred stock issue, net of issuance costs, 4/30/2002; 250,000 shares at \$10.00 per share	250,000	250	--
Preferred stock dividend, April 30, 2002	--	--	--
Preferred stock issue, net of issuance costs, 7/31/2002; 250,000 shares at \$10.00 per share	250,000	250	--
Collection of subscription receivable	--	--	--
Options issued for consulting services,			

Edgar Filing: ASTRALIS LTD - Form 10KSB

9/10/2002; 15,000 options at \$0.38 per option, based on valuation	--	--	--
Preferred stock dividend, 12/10/2002	--	--	--
Amortization of deferred compensation	--	--	--
Fair value adjustment on deferred compensation	--	--	--
COMPREHENSIVE LOSS			
Net loss	--	--	--
Other comprehensive loss:			
Unrealized gain (loss) on available-for-sale securities	--	--	--
	-----	-----	-----
Total Comprehensive Loss			
Balance, December 31, 2002	1,750,000	\$ 1,750	37,538,189
	=====	=====	=====

See the accompanying notes to financial statements

F-7

ASTRALIS LTD.
(A Development Stage Entity)
Statements of Stockholders' Equity

	Subscription Receivable	Deferred Compensation	Accumulated Other Comprehensive Loss
	-----	-----	-----
Balances Brought Forward	\$ (1,350,000)	\$ (398,250)	\$ --
Oversubscription of common stock issued in private placement, 11/13/2001; 49,990 shares cancelled at \$1.60 per share, 1/24/2002	--	--	--
Preferred stock issue, net of issuance costs, 1/31/2002; 250,000 shares at \$10.00 per share	--	--	--
Preferred stock issue, net of issuance costs, 4/30/2002; 250,000 shares at \$10.00 per share	--	--	--
Preferred stock dividend, April 30, 2002	--	--	--
Preferred stock issue, net of issuance costs, 7/31/2002; 250,000 shares at \$10.00 per share	--	--	--

Edgar Filing: ASTRALIS LTD - Form 10KSB

Collection of subscription receivable	465,000	--	--
Options issued for consulting services, 9/10/2002; 15,000 options at \$0.38 per option, based on valuation	--	(5,700)	--
Preferred stock dividend, 12/10/2002	--	--	--
Amortization of deferred compensation	--	34,254	--
Fair value adjustment on deferred compensation	--	357,532	--
COMPREHENSIVE LOSS			
Net loss	--	--	--
Other comprehensive loss:			
Unrealized loss on available-for-sale securities	--	--	(15,181)
	-----	-----	-----
Total Comprehensive Loss			
Balance, December 31, 2002	\$ (885,000)	\$ (12,164)	\$ (15,181)
	=====	=====	=====
	Deficit Accumulated During the Development Stage	Total	Total Comprehensive Loss
	-----	-----	-----
Balances Brought Forward	\$ (6,195,364)	\$ 9,074,368	
Oversubscription of common stock issued in private placement, 11/13/2001; 49,990 shares cancelled at \$1.60 per share, 1/24/2002	--	(80,000)	
Preferred stock issue, net of issuance costs, 1/31/2002; 250,000 shares at \$10.00 per share	--	2,500,000	
Preferred stock issue, net of issuance costs, 4/30/2002; 250,000 shares at \$10.00 per share	--	2,500,000	
Preferred stock dividend, April 30, 2002	(270,000)	--	(270,000)
Preferred stock issue, net of issuance costs, 7/31/2002; 250,000 shares at \$10.00 per share	--	2,500,000	
Collection of subscription receivable	--	465,000	
Options issued for consulting services, 9/10/2002; 15,000 options at \$0.38 per option, based on valuation	--	--	
Preferred stock dividend, 12/10/2002	(9,078,750)	--	(9,078,750)

Edgar Filing: ASTRALIS LTD - Form 10KSB

Amortization of deferred compensation	--	34,254	
Fair value adjustment on deferred compensation	--	--	
COMPREHENSIVE LOSS			
Net loss	(9,040,248)	(9,040,248)	\$ (9,040,248)
Other comprehensive loss:			
Unrealized loss on available-for-sale securities	--	(15,181)	(15,181)
	-----	-----	-----
Total Comprehensive Loss			\$ (18,404,179)
			=====
Balance, December 31, 2002	\$ (24,584,362)	\$ 7,938,193	
	=====	=====	

See the accompanying notes to financial statements

F-8

ASTRALIS LTD.
(A Development Stage Entity)
Statements of Stockholders' Equity

	Preferred Stock		Common
	Shares	Amount	Shares
	-----	-----	-----
Balances Brought Forward	1,750,000	\$ 1,750	37,538,189
Preferred stock issue, net of issuance costs, 1/31/2003; 250,000 shares at \$10.00 per share	250,000	250	--
Collection of subscription receivable	--	--	--
Reduction of subscription receivable, in lieu of payment for services	--	--	--
Amortization of deferred compensation	--	--	--
Fair value adjustment on deferred compensation	--	--	--
Offering cost for January 2004 private placement	--	--	--
COMPREHENSIVE LOSS			
Net loss	--	--	--
Other comprehensive loss:			

Edgar Filing: ASTRALIS LTD - Form 10KSB

Unrealized gain (loss) on available-for-sale securities	--	--	--
	-----	-----	-----
Total Comprehensive Loss			
Balance, December 31, 2003	2,000,000	\$ 2,000	37,538,189
	=====	=====	=====

See the accompanying notes to financial statements

F-9

ASTRALIS LTD.
(A Development Stage Entity)
Statements of Stockholders' Equity

	Subscription Receivable	Deferred Compensation	Accumulated Other Comprehensive Loss
	-----	-----	-----
Balances Brought Forward	\$ (885,000)	\$ (12,164)	\$ (15,181)
Preferred stock issue, net of issuance costs, 1/31/2003; 250,000 shares at \$10.00 per share			
Collection of subscription receivable,	825,000	--	--
Reduction of subscription receivable, in lieu of payment for services	36,000	--	--
Amortization of deferred compensation	--	25,663	--
Fair value adjustment on deferred compensation	--	(18,321)	--
Offering cost for January 2004, private placement	--	--	--
COMPREHENSIVE LOSS			
Net loss	--	--	--
Other comprehensive loss:			
Unrealized gain (loss) on available-for-sale Securities, net	--	--	(12,517)
	-----	-----	-----
Total Comprehensive Loss			
Balance, December 31, 2003	\$ (24,000)	\$ (4,822)	\$ (27,698)
	=====	=====	=====

Edgar Filing: ASTRALIS LTD - Form 10KSB

	Deficit Accumulated During the Development Stage	Total	Total Comprehensiv Loss
	-----	-----	-----
Balances Brought Forward	\$ (24,584,362)	\$ 7,938,193	
Preferred stock issue, net of issuance costs, 1/31/2003; 250,000 shares at \$10.00 per share		2,500,000	
Collection of subscription receivable,	--	825,000	
Reduction of subscription receivable, in lieu of payment for services	--	36,000	
Amortization of deferred compensation	--	25,663	
Fair value adjustment on deferred compensation	--	--	
Offering cost for January 2004, private placement	--	(17,603)	
COMPREHENSIVE LOSS			
Net loss	(5,080,427)	(5,080,427)	\$ (5,080,427)
Other comprehensive loss:			
Unrealized gain (loss) on available-for-sale Securities, net	--	(12,517)	(12,517)
	-----	-----	-----
Total Comprehensive Loss			\$ (5,092,944)
			=====
Balance, December 31, 2003	\$ (29,664,789)	\$ 6,214,309	
	=====	=====	

See the accompanying notes to financial statements

F-10

ASTRALIS LTD.
(A Development Stage Entity)
Statements of Stockholders' Equity

	Preferred Stock		Comm
	Shares	Amount	Shares
	-----	-----	-----
Balances Brought Forward	2,000,000	\$ 2,000	37,538,189

Edgar Filing: ASTRALIS LTD - Form 10KSB

Common stock issue, net of issuance costs, Jan-Feb 2004 at \$2.00 per share	--	--	10,459,866
Collection of subscription receivable	--	--	--
Conversion of Preferred Stock, Series A	(2,000,000)	(2,000)	25,000,000
Preferred stock dividend	--	--	--
Common stock issued, in lieu of payment for services	--	--	150,000
Call option assigned, in lieu of payment for services	--	--	--
Amortization of deferred compensation	--	--	--
Fair value adjustment on deferred compensation	--	--	--
Stock options exercised	--	--	25,000
COMPREHENSIVE LOSS			
Net loss	--	--	--
Other comprehensive loss:			
Unrealized gain (loss) on available-for-sale securities	--	--	--
	-----	-----	-----
Total Comprehensive Loss			
Balance, December 31, 2004	--	\$ --	73,173,055
	=====	=====	=====

See the accompanying notes to financial statements

F-11

ASTRALIS LTD.
(A Development Stage Entity)
Statements of Stockholders' Equity

	Subscription Receivable	Deferred Compensation	Accumulated Other Comprehensive Loss
	-----	-----	-----
Balances Brought Forward	\$ (24,000)	\$ (4,823)	\$ (27,698)
Common stock issue, net of issuance costs, Jan -Feb 2004 at \$2.00 per share	--	--	--

Edgar Filing: ASTRALIS LTD - Form 10KSB

Collection of subscription receivable,	24,000	--	--
Conversion of Preferred Stock, Series A	--	--	--
Preferred stock dividend	--	--	--
Common stock issued, in lieu of payment for services	--	--	--
Call option assigned, in lieu of payment for services	--	--	--
Amortization of deferred compensation	--	4,823	--
Fair value adjustment on deferred compensation	--	--	--
Stock options exercised	--	--	--
COMPREHENSIVE LOSS			
Net loss	--	--	--
Other comprehensive loss:			
Unrealized gain (loss) on available-for-sale securities, net	--	--	27,698
	-----	-----	-----
Total Comprehensive Loss			
Balance, December 31, 2004	\$ --	\$ --	\$ --
	=====	=====	=====
	Deficit Accumulated During the Development Stage	Total	Total Comprehensiv Loss
	-----	-----	-----
Balances Brought Forward	\$ (29,664,789)	\$ 6,214,308	
Common stock issue, net of issuance costs, Jan -Feb 2004 at \$2.00 per share	--	4,954,193	
Collection of subscription receivable,	--	24,000	
Conversion of Preferred Stock, Series A	--	--	
Preferred stock dividend	(10,750,000)	--	\$ (10,750,000)
Common stock issued, in lieu of payment for services	--	75,000	
Call option assigned, in lieu of payment for services	--	376,507	
Amortization of deferred compensation	--	4,823	

Edgar Filing: ASTRALIS LTD - Form 10KSB

Fair value adjustment on deferred compensation	--	--	
Stock options exercised	--	11,250	
COMPREHENSIVE LOSS			
Net loss	(9,287,568)	(9,287,568)	(9,287,568)
Other comprehensive loss:			
Unrealized gain (loss) on available-for-sale securities, net	--	27,698	27,698
	-----	-----	-----
Total Comprehensive Loss			\$ (20,009,870)
			=====
Balance, December 31, 2004	\$ (49,702,357)	\$ 2,400,211	
	=====	=====	

See the accompanying notes to financial statements

F-12

ASTRALIS LTD.
(A Development Stage Entity)
Statements of Stockholders' Equity

	Preferred Stock		Common Stock	
	Shares	Amount	Shares	Amount
	-----	-----	-----	-----
Balances Brought Forward	--	\$ --	73,173,055	\$ --
Common stock issued for services-officer	--	--	100,000	--
Common stock issue, net of issuance costs, August 2005 at \$0.11 per share	--	--	18,181,818	--
COMPREHENSIVE LOSS				
Net loss	--	--	--	--
Other comprehensive loss:				
Unrealized gain (loss) on available-for-sale securities	--	--	--	--
	-----	-----	-----	-----
Total Comprehensive Loss				
Balance, December 31, 2005	--	\$ --	91,454,873	\$ --
	=====	=====	=====	=====

Edgar Filing: ASTRALIS LTD - Form 10KSB

See the accompanying notes to financial statements

F-13

ASTRALIS LTD.
(A Development Stage Entity)
Statements of Stockholders' Equity

	Subscription Receivable	Deferred Compensation	Accumulated Other Comprehensive Loss
	-----	-----	-----
Balances Brought Forward	\$ --	\$ --	\$ 000
Common stock issued for services-officer	--	--	--
Common stock issue, net of issuance costs, August 2005 at \$0.11 per share	--	--	--
COMPREHENSIVE LOSS			
Net loss	--	--	--
Other comprehensive loss:			
Unrealized gain (loss) on available-for-sale securities, net	--	--	--
	-----	-----	-----
Total Comprehensive Loss			
Balance, December 31, 2005	\$ -- =====	\$ -- =====	\$ -- =====
	Deficit Accumulated During the Development Stage	Total	Total Comprehensive Loss
	-----	-----	-----
Balances Brought Forward	\$(49,702,357)	\$ 2,400,211	
Common stock issued for services-officer	--	65,000	
Common stock issue, net of issuance costs, August 2005 at \$0.11 per share	--	1,830,000	
COMPREHENSIVE LOSS			
Net loss	(3,914,159)	(3,914,159)	\$ (3,914,159)

Edgar Filing: ASTRALIS LTD - Form 10KSB

Other comprehensive loss:

Unrealized gain (loss) on available-for-sale securities, net	--	--	--
	-----	-----	-----
Total Comprehensive Loss			\$ (3,914,159)
			=====
Balance, December 31, 2005	\$ (53,616,516)	\$ 381,052	
	=====	=====	

See the accompanying notes to financial statements

F-14

ASTRALIS LTD.
(A Development Stage Entity)
Statements of Cash Flows

	Year Ended

	2005

Cash Flows from Operating Activities	
Net loss	\$ (3,914,159)
Adjustments to reconcile net loss to net cash used in operating activities	
Depreciation and amortization	122,282
Impairment of intangible asset	114,976
Amortization of net premium paid on investments	--
Dividend income reinvested	--
Members' contributed salaries	--
Research and development service fee netted against proceeds received from preferred stock issuance	--
Operating expenses paid by related parties on behalf of company	--
Amortization of deferred compensation	--
Investor relation fees netted against subscription receivable	--
Compensatory common stock	65,000
Assignment of call option	--
Loss on sale of available-for-sale securities and fixed asset retirement	--
Changes in assets and liabilities	
Prepaid expenses	6,688
Interest receivable	--
Supplies	23,743
Deposits	1,763
Accounts payable and accrued expenses	77,340

Net Cash Used in Operating Activities	(3,502,367)

Cash Flows from Investing Activities	
Purchases of available-for-sale securities	--
Proceeds from sale of available-for-sale securities	--
Expenditures related to patent	(4,113)
Insurance proceeds from claim	--

Edgar Filing: ASTRALIS LTD - Form 10KSB

Purchases of property and equipment	(2,453)

Net Cash (Used in) Provided by Investing Activities	(6,566)

Cash Flows from Financing Activities	
Repurchase of common stock	--
Collection of subscription receivable	--
Proceeds from exercise of stock options	--
Issuance of common stock, net of offering and transaction costs	1,830,000
Issuance of preferred stock	--
Private placement offering costs	--

Net Cash Provided by Financing Activities	1,830,000

Net Increase (Decrease) in Cash and Cash Equivalents	(1,678,933)
Cash and Cash Equivalents, Beginning of Period	2,312,401

Cash and Cash Equivalents, End of Period	\$ 633,468
	=====

See the accompanying notes to financial statements

F-15

Astralis, Ltd.
(A Development Stage Entity)
NOTES TO FINANCIAL STATEMENTS

NOTE 1 - DESCRIPTION OF BUSINESS

Nature of Operations

Astralis, Ltd. (the "Company") is an emerging stage biotechnology company, based in New Jersey and incorporated under the laws of the State of Delaware, which primarily engages in research and development of treatments for immune system disorders and skin diseases. The Company is currently developing two products. Its primary product, Psoraxine(R), administered by intramuscular injection, is an innovative immunotherapeutic product under development for the treatment of psoriasis. The Company's second product is for the treatment of arthritis. The Company is engaged in on-going research and development of Psoraxine(R), and expects to recommence clinical trials to obtain the approval of the United States Food and Drug Administration for the marketing of Psoraxine(R), and development of the technology underlying the Psoraxine(R), for the treatment of other indications, such as eczema, leishmaniasis and seborrheic dermatitis.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The Company's financial statements are prepared on the accrual basis of accounting in accordance with United States generally accepted accounting principles ("US GAAP").

Edgar Filing: ASTRALIS LTD - Form 10KSB

Development Stage Enterprise

The Company is a Development Stage Enterprise, as defined in Statement of Financial Accounting Standards No. 7 "Accounting and Reporting for Development Stage Enterprises" ("SFAS No. 7"). Under SFAS No. 7, certain additional financial information is required to be included in the financial statements for the period from inception of the Company to the current balance sheet date.

Since the inception of the Company, management has been in the process of performing research and development activities, fulfilling FDA requirements in order to enter human clinical trials in the US with Psoraxine(R), initiating Phase I clinical studies and the raising of capital through private placement stock offerings.

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents include cash on hand and investments in money market funds. The Company considers all highly liquid instruments with an original maturity of 90 days or less at the time of purchase to be cash equivalents.

F-16

Astralis, Ltd.
(A Development Stage Entity)
NOTES TO FINANCIAL STATEMENTS

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash deposits at financial institutions. To mitigate this risk, the Company places its cash deposits only with high credit quality institutions.

Property and Equipment

Furniture and equipment are recorded at cost, less accumulated depreciation computed on a straight-line basis over the estimated useful lives of the respective assets. Depreciation is computed using a four-year life for computer and office equipment, three to four years for lab equipment, seven-year for furniture and fixtures and three-year for leasehold improvements.

Income Taxes

Income taxes are recorded in the period in which the related transactions are recognized in the financial statements, net of the valuation allowances, which have been recorded against deferred tax assets. Deferred tax assets and liabilities are recorded for the expected future tax consequences of temporary differences between the tax basis and the financial reporting of assets and liabilities. Net deferred tax assets and liabilities, relating primarily to

Edgar Filing: ASTRALIS LTD - Form 10KSB

federal and state net operating loss carryforwards and research and development credits that have been deferred for tax purposes have also been recorded. A valuation reserve has been recorded to offset a portion of the deferred tax benefit (except for amount realized through the sale of a portion of the Company's New Jersey net operating loss) because management has determined it is more likely than not that the deferred tax assets will not be realized. See Note 6.

Stock-Based Compensation Arrangements

The Company applies the intrinsic value method of accounting prescribed by Accounting Principles Board Opinion No. 25, "Accounting For Stock Issued To Employees," and related interpretations, in accounting for its stock-based grants to employees and directors. Under the intrinsic value method of accounting, compensation expense is recorded on the date of grant only if the current market price of the underlying stock exceeds the exercise price. The Company applies the disclosure provisions specified in SFAS No. 148, "Accounting For Stock Based Compensation - Transition and Disclosure - an Amendment of SFAS 123." The Company applies SFAS No. 123, "Accounting for Stock-Based Compensation," in accounting for stock-based grants to non-employees.

The following table illustrates the effect on net loss and earnings per share if the Company had applied the fair value recognition provisions of Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based Compensation," to stock-based compensation.

F-17

Astralis, Ltd.
(A Development Stage Entity)
NOTES TO FINANCIAL STATEMENTS

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

	Year Ended December	Year Ended
	2005	
	-----	-----
Net loss, as reported	\$ (3,914,159)	\$ (20,000,000)
Add:		
Stock-based compensation expense included in reported net loss determined under APB No. 25, net of related tax effects	--	
Deduct:		
Total stock-based director compensation expense determined under fair-value-based method for all awards, net of related tax effects	272,545	
	-----	-----
Pro forma net loss	\$ (4,186,704)	\$ (20,000,000)
	=====	=====
Loss per share:		
Basic - as reported	\$ (0.05)	\$ (0.05)
Basic - pro forma	\$ (0.05)	\$ (0.05)

Edgar Filing: ASTRALIS LTD - Form 10KSB

These pro forma amounts may not be representative of future disclosures since the estimated fair value of stock options is amortized to expense over the vesting period and additional options may be issued in future years. The estimated fair value of each option granted was calculated using the Black-Scholes option-pricing model. The following summarizes the weighted average of the assumptions used in the model.

	2005 -----	2004 -----
Risk free rate	4.12%	4.13%
Expected years until exercise	9.82	9.614
Expected stock volatility	103.41%	100.0%

Loss Per Share

Loss per common share is calculated in accordance with Statement of Financial Accounting Standards No. 128, Earnings Per Share ("FAS 128"). Basic loss per common share is computed based upon the weighted average number of shares of common stock outstanding for the period and excludes any potential dilution. Shares associated with stock options, warrants and convertible preferred stock are not included because their inclusion would be antidilutive (i.e., reduce the net loss per share).

The common shares potentially issuable arising from these instruments, which were outstanding during the periods presented in the financial statements, consisted of:

	2005 -----	2004 -----
Options	1,454,000	1,118,000
Warrants	46,759,466	18,151,891
	-----	-----
	48,213,466	19,269,891
	=====	=====

F-18

Astralis, Ltd.
(A Development Stage Entity)
NOTES TO FINANCIAL STATEMENTS

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Segment Information

The Company has determined it has one reportable operating segment as defined by Statement of Financial Accounting Standards No. 131, "Disclosures about Segments of an Enterprise and Related Information."

Research and Development Costs

The cost of research, development and product improvement expenditures, which includes depreciation of the Company's laboratory and amortization of the technology access option, are charged to expense as they are incurred. Research, development and product improvement costs included in operating expenses amounted to \$2,510,521 and \$7,689,060 for the years ending December 31, 2005 and 2004, respectively; and \$25,238,571 for the period from March 12, 2001 (date of inception) to December 31, 2005.

Edgar Filing: ASTRALIS LTD - Form 10KSB

Included in this amount were payments to related parties (see Note 10). Also included in the December 31, 2005 and 2004 year ends is an impairment of intangible assets for \$114,976 and \$2,797,612, respectively. For the period from March 12, 2001 (date of inception) to December 31, 2005 amount, is an impairment of intangible assets of \$2,912,588. (see Note 4).

Recent Accounting Pronouncements

In December 2004, accounting standards were revised and now require all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values. The pro forma disclosures previously permitted will no longer be an alternative to financial statement recognition. The new accounting standard is effective for fiscal years beginning after June 15, 2005. The guidance also provides for classifying awards as either liabilities or equity, which impacts when and if the awards must be remeasured to fair value subsequent to the grant date. We adopted the new accounting standard effective January 1, 2006.

The impact of adoption on our reported results of operations for future periods will depend on the level of share-based payments granted in the future. However, had we adopted the revised accounting standards in prior periods, the impact of that standard would have approximated the impact as described in the disclosure of pro forma net loss and net loss per share in the table included in Stock-Based Compensation Arrangements in Note 2 to the Consolidated Financial Statements. Also, benefits of tax deductions in excess of recognized compensation costs will be reported as financing cash flow, rather than as an operating cash flow as required under current literature. This requirement will reduce net operating cash flows and increase net financing cash flows in periods after adoption. We believe this reclass will not have a material impact on our Consolidated Statements of Cash Flows.

F-19

Astralis, Ltd.
(A Development Stage Entity)
NOTES TO FINANCIAL STATEMENTS

NOTE 3 - GOING CONCERN

The Company incurred net losses to common stockholders of \$3,914,159 in 2005 and had an accumulated deficit of \$53,616,516 at December 31, 2005. Included in the cumulative net losses was non-cash preferred stock dividend generated from beneficial conversion features of preferred stock in the amount of \$22,218,750. (See Note 7)

Pharmaceutical products must undergo an extensive process, including testing in compliance with U.S. Food and Drug Administration ("FDA") regulations, before they can be commercially sold and distributed in the United States. FDA testing occurs in various phases over a multiple number of years. The Company expects to continue clinical testing of Psoraxine in 2006. The Company will need significant additional funds to complete all of the testing required by the FDA. Currently, the Company has no products approved for commercial sale and therefore no means to generate revenue.

On March 14, 2005, the Company issued a press release to disclose the results of its Phase II study for Psoraxine. The Phase II study of its novel immuno-stimulatory product for the treatment of Psoriasis indicated no statistical difference between the Company's product and a placebo. In the study, Psoraxine was found to be safe and well tolerated.

Edgar Filing: ASTRALIS LTD - Form 10KSB

Based on an analysis of the data from its Phase II study the Company has developed a hypothesis to explain why the results differed from the long-term improvement of the more than 2,700 patients who were treated with Psoraxine in pre-clinical studies. The Company intends to reformulate the product and reproduce the clinical studies performed in Venezuela using the formula deployed in the Venezuelan trials. The Company hopes to demonstrate an outcome that is more consistent with results from pre-clinical studies.

Consequently, the aforementioned items raise substantial doubt about the Company's ability to continue as a going concern.

The Company raised \$2,000,000 additional capital in August 2005 through a private placement equity offering. These funds, in addition to its cash held at December 31, 2005, are sufficient to finance the Company's needs for operating and capital expenditures through May 2006. The Company will need to raise significant additional funds from outside sources immediately and in future years in order to complete existing and future phases of FDA required testing.

Management is seeking to identify additional capital immediately so that it may continue its operations. These funds will be needed in order to finance the Company's currently anticipated needs for operating and capital expenditures for 2006, including the cost to continue clinical trials of Psoraxine(R) and initiate development of pipeline products to treat arthritis and leishmaniasis. The Company will also need to raise significant additional funds from outside sources in future years in order to complete existing and future phases of FDA required testing.

The Company's ability to continue as a going concern is dependent upon it raising capital immediately through debt and/or equity financing. There can be no assurance that the Company will successfully raise the required future financing on terms desirable to the Company or that the FDA will approve Psoraxine for use in the United States. If the Company does not obtain the needed funds, it will be required to cease operations. The Company is actively seeking sources of financing. The Company is considering and will implement further dramatic cost reduction measures to extend the availability of its capital. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets and amounts and classifications of liabilities that might result from the outcome of this uncertainty.

F-20

Astralis, Ltd.
(A Development Stage Entity)
NOTES TO FINANCIAL STATEMENTS

NOTE 4 - INTANGIBLE ASSETS

The Company's policy is to capitalize the costs of purchased and internally developed patents and those expenses in connection with patent rights licensed to the Company. The life of the patent is 20 years from the date the patent is applied for or 17 years from when it is granted, whichever is longer. The Company's policy is to capitalize direct costs related to the rights it has licensed, and amortize them on a straight-line basis over the remaining portion of the 20-year period, which commenced on March 16, 2001, the date the application was filed for the patent the Company has licensed

The Company paid \$5,000,000 for a technology access option from SkyePharma PLC ("SkyePharma"). This option gives the Company the right, until December 10,

Edgar Filing: ASTRALIS LTD - Form 10KSB

2008, to enter into a non-exclusive license agreement to utilize any of three drug delivery systems of SkyePharma in connection with any drugs it develops to treat two specific immunotherapies. Upon exercise of the option, the Company will be required to pay a license fee of 5% of net sales of any product utilizing the drug delivery systems. All other terms of the license agreement will be determined upon exercise of the option.

The Company evaluated this intangible annually for impairment under FAS 144 "Accounting For The Impairment or disposal of Long-Lived Assets" and has determined that as of December 31, 2004, the technology access option fee has no market value due to current market conditions and impaired the remaining unamortized amount. Current market conditions dictate the license fee no longer has a market value because it has become common business practice for companies who provide drug delivery systems to offer their systems, on a trial basis, without charge, for the purpose of testing effectiveness of the delivery system in an effort to obtain rights to distribute new drugs.

The Company has amortized \$7,061 and \$6,362 of patent costs and \$0 and \$714,288 of the cost of the technology option license in 2005 and 2004, respectively. The Company recorded impairment charges in the amount of \$2,797,612 in 2004 as a result of the technology option license having no substantial market value. In addition, the Company recorded impairment charges in the amount of \$114,976 in 2005 pertaining to the patents under the accounting guidance in SFAS 144. The amortization and impairment related to the technology option license and patent is recorded as research and development cost as required by SFAS No. 2.

Intangible assets consisted of the following at December 31,

	2005	2004
	-----	-----
Patent	\$ 134,222	\$ 130,109
Technology access fee	5,000,000	5,000,000
Less impairment	(2,912,588)	(2,797,612)
Less accumulated amortization	(2,221,634)	(2,214,574)
	-----	-----
	\$ --	\$ 117,923
	=====	=====

F-21

Astralis, Ltd.
(A Development Stage Entity)
NOTES TO FINANCIAL STATEMENTS

NOTE 5 - PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at December 31,

	2005	2004
	-----	-----
Furniture and Fixtures	\$ 28,281	\$ 28,281
Computer Equipment	32,930	30,477
Leasehold Improvements	199,741	199,741
Lab Equipment	299,066	299,066
Automobiles	--	--
	-----	-----
	\$ 560,018	\$ 557,565

Edgar Filing: ASTRALIS LTD - Form 10KSB

Accumulated depreciation and amortization	(458,647)	(343,425)
	-----	-----
	\$ 101,371	\$ 214,140
	=====	=====

Depreciation expense amounted to \$115,222 and \$147,252 for the years ended December 31, 2005 and 2004, respectively. The depreciation related to the Company's laboratory and related equipment is recorded as research and development as required by SFAS No. 2.

NOTE 6 - INCOME TAXES

Deferred income taxes reflect the net tax effects of temporary timing differences between the carrying amounts of assets and liabilities reflected on the financial statements and the amounts used for income tax purposes. The tax effects of temporary differences and net operating loss carryforwards and tax credits that give rise to significant portions of the deferred tax assets recognized are presented below:

	2005	2004
	-----	-----
Deferred tax assets :		
Prepaid research and development	\$ --	\$ --
Deferred compensation	82,400	76,500
Accumulated depreciation and amortization	1,551,600	1,613,200
Research and development credits carryforward	2,073,600	1,974,300
Federal and state deferred tax benefit arising from net operating loss carryforwards	9,672,300	8,370,600
	-----	-----
	13,379,900	12,034,600
Less valuation allowance	(13,379,900)	(12,034,600)
	-----	-----
Total deferred tax assets	\$ --	\$ --
	=====	=====

F-22

Astralis, Ltd.
(A Development Stage Entity)
NOTES TO FINANCIAL STATEMENTS

NOTE 6 - INCOME TAXES (Continued)

As of December 31, 2005, the Company had losses, which resulted in net operating loss carryforwards for tax purposes amounting to approximately \$25,900,000 that may be offset against future taxable income. These carryforwards start to expire in 2021. The Company generated federal research and development credits of \$1,416,500 that will expire in 2021 and state credits of \$657,000 that will expire in 2008. However, these carryforwards and credits may be significantly limited due to changes in the ownership of the Company as a result of future equity offerings.

Edgar Filing: ASTRALIS LTD - Form 10KSB

Recognition of the benefits of the deferred tax assets and liabilities will require that the Company generate future taxable income. There can be no assurance that the Company generates any earnings or any specific level of earnings in future years. Therefore, the Company has established a valuation allowance for deferred tax assets (net of liabilities) of approximately \$13,379,900 and \$12,034,600 as of December 31, 2005 and 2004.

In 2005 and 2004, the Company sold \$3,965,391 and \$3,791,489, respectively, of its gross New Jersey net operating loss carryforwards under the State of New Jersey's Technology Business Tax Certificate Transfer Program (the "Program"). The Program allows qualified technology and biotechnology businesses in New Jersey to sell unused amounts of net operating loss carryforwards and defined research and development tax credits for cash. The proceeds from the sale of the Company's carryforwards were \$306,921 and \$293,461, respectively (net of fees) and the amount was recorded as a tax benefit in the statements of operations. The State of New Jersey renews the Program annually and limits the aggregate proceeds of the program to \$10,000,000. Due to the uncertainty at any time as to the Company's ability to effectuate the sale of available New Jersey net operating losses, and since the Company has no control or influence over the Program, the benefits are recorded once the agreement with the counterpart is signed and the sale is approved by the State.

In accordance with federal income tax regulations, the net loss incurred by Astralis, LLC (the predecessor entity) from inception to the date of its merger with the Company has been excluded from the benefits of the net operating loss carryforwards reflected in this footnote.

The following table presents the principal reasons for the difference between the Company's effective tax rates and the United States federal statutory income tax rate of 34%.

	2005	2004
	-----	-----
Federal income tax benefit at statutory rate	\$ 1,302,600	\$ 3,257,550
State income tax benefit (net of effect of federal benefit)	221,700	446,600
Non-deductible expenses	(317,300)	(170,650)
Research and development credit	99,300	848,900
Valuation allowance	(1,306,300)	(4,382,400)
Benefit from sale of state net operating loss	306,900	293,500
	-----	-----
Income Tax Benefit	\$ 306,900	\$ 293,500
	=====	=====
Effective Income Tax Rate	(9%)	(9)
	=====	=====

F-23

Astralis, Ltd.
(A Development Stage Entity)
NOTES TO FINANCIAL STATEMENTS

NOTE 7 - CAPITAL STOCK ACTIVITY

Common Stock

Edgar Filing: ASTRALIS LTD - Form 10KSB

In 2001 Astralis LLC (the predecessor entity) and the Company merged and this transaction was treated as a recapitalization of the Company, whereby the Company issued to the members of Astralis, LLC, 28,000,000 shares of common stock and warrants to purchase 6,300,000 shares of Company common stock for \$1.60 per share in a one-for-one exchange for all of the outstanding 28,000,000 Astralis, LLC member units of ownership and 6,300,000 options to purchase member units.

Prior to the Merger

Astralis LLC issued 25,300,000 units on April 25, 2001 to various members for an aggregate subscription receivable amount of \$33,183. During the year, the members paid \$33,183 on behalf of the Company to satisfy their subscription receivable.

In April 2001, the Company issued warrants to purchase 75,000 shares of common stock at an exercise price of \$1.75 per share. These warrants expired in April 2004.

On September 1, 2001, five new members were admitted as members of the LLC through the execution of a subscription agreement. These new members subscribed to units ("Units") from Astralis LLC consisting of an aggregate of 2,700,000 membership interests (the "Membership Interests") in Astralis LLC and 6,300,000 options to purchase additional Membership Interests in Astralis LLC for an exercise price of \$1.60 per Membership Interest.

On November 13, 2001, the aforementioned Units were exchanged for an aggregate of 2,700,000 shares of our common stock and warrants to purchase 6,300,000 shares of common stock at an exercise price of \$1.60 per share. The aggregate purchase price for such Units was \$1,350,000 and was paid with subscription notes. Warrants to purchase 3,150,000 shares of common stock, as amended, were to expire on December 13, 2004 and 3,150,000 expire November 13, 2006. The 3,150,000 warrants that were set to expire on December 13, 2004 were extended to February 18, 2005 and subsequently extended to March 11, 2005 when they expired.

In September 2001, Astralis, LLC granted 500,000 membership units to a consultant in return for services rendered. The membership units were subsequently exchanged for shares of common stock of the Company. The cost of the services, based on an independent valuation of the units granted, which amounted to \$135,000, were recorded at the time the services were rendered in 2001.

Subsequent to Merger

In November 2001, the Company completed a \$3,321,887 private placement offering pursuant to which it sold 103.81 units at \$32,000 per unit for an aggregate amount of \$3,321,887. Each unit consisted of 20,000 shares of common stock and warrants to purchase 4,000 shares of the Company's common stock at \$4.00 per share. The warrants expire on November 13, 2006. The holders of these shares of common stock and warrants received registration rights. The Company was required to file a registration statement by March 13, 2002 to register the sale of these shares and the shares underlying the warrants. Upon consummation of the private placement, the Company paid a \$100,000 investment banking fee and entered into an agreement for future investment banking services amounting to \$144,000, payable in 24 equal monthly installments of \$6,000.

Edgar Filing: ASTRALIS LTD - Form 10KSB

(A Development Stage Entity)
NOTES TO FINANCIAL STATEMENTS

NOTE 7 - CAPITAL STOCK ACTIVITY (Continued)

In January 2002, the Company agreed to amend a subscription agreement with one of the investors who participated in the November 2001 private placement offering. The Company consented to reduce the number of shares in the subscription agreement by 49,990 shares of common stock. The Company cancelled the respective shares and returned the corresponding amount of funds to the investor amounting to \$80,000.

In 2002 and 2003, the Company collected \$465,000 and \$825,000 in cash of the subscription receivables, respectively. In April 2003, the Company entered into the Amended Investor Relation Agreement with one of the stockholders who has outstanding subscription receivable with the Company. The Company agreed to receive services in lieu of payment of the outstanding subscription receivable in the amount of \$60,000. In 2004 and 2003, the Company received services valued at \$24,000 and \$36,000, respectively.

On December 15, 2003, the Company amended its Articles of Incorporation to authorize the issuance of 150,000,000 shares of common stock, \$0.0001 par value per share, and 3,000,000 shares of Series A preferred stock, \$0.001 par value of which 73,173,055 shares of common and 0 share of Series A preferred were outstanding as of December 31, 2004.

On January 20, 2004, the Company closed a private placement from which it received gross proceeds of approximately \$4,080,000. The transaction consisted of the sale to accredited investors of units consisting of 8,159,964 shares of common stock and warrants to purchase 8,159,964 shares of common stock. The warrants have an exercise price of \$0.73 and expire in four years.

On February 19, 2004, the Company closed the second round of its private placement from which it received \$1,150,000. The transaction consisted of sales to accredited investors of units consisting of 2,299,902 shares of common stock and warrants to purchase 2,299,902 shares of common stock. The warrants have an exercise price of \$0.73 and expire in four years.

FPP Capital Advisors whose sole shareholder is a director of the Company was paid a consulting fee in the amount of \$261,496 in February 2004 for the consulting services related to the private placement completed in 2004. In addition, the related party and his assignees received warrants to purchase an aggregate of 418,394 shares of the Company's common stock at \$0.50 per share and warrants to purchase an aggregate of 418,394 shares of the Company's common stock at \$0.73 per share. An additional consulting fee equal to 5% of proceeds received will be paid upon exercise of the warrants issued in the private placements. The warrants expire in four years.

The Company issued to FPP Capital Advisors (a related party) 150,000 shares of common stock and warrants to purchase 150,000 shares of common stock for consulting services valued at \$75,000. The warrants have an exercise price of \$0.73 and expire in five years. In addition, in connection with the conversion by SkyePharma of its shares of the Company's Series A Preferred Stock, the Company assigned to FPP Capital Advisors, as compensation, 10% of the call option provided to the Company under the call option agreement dated January 20, 2004 between the Company and SkyePharma. Accordingly, the Company recorded a non-cash charge of \$376,508 in June 2004.

On July 9, 2004 a director of the Company exercised options to purchase 25,000 shares of common stock at \$0.45 a share. The shares issued remain restricted.

Edgar Filing: ASTRALIS LTD - Form 10KSB

F-25

Astralis, Ltd.
(A Development Stage Entity)
NOTES TO FINANCIAL STATEMENTS

NOTE 7 - CAPITAL STOCK ACTIVITY (Continued)

In the first quarter of 2005 SkyePharma purchased the 11,160,000 shares of common stock from Mike Ajnsztajn and Gaston Liebhaber. Consequently, as of March 3, 2005 SkyePharma owned approximately 49.7% of the Company's outstanding common stock.

In January 2005, the Company issued 100,000 shares of the Company's common stock along with 728,000 options to James Sharpe, the Company's former Chief Executive Officer and President. The options were issued with an exercise price of \$0.70 with a term of 10 years. The options vest over three years, with 25% vesting on the date of the grant and 25% vesting on the anniversary of the grant date until fully vested. On January 25, 2006, Mr. Sharpe entered into a "Separation Agreement and General Release" with the Company and resigned as Chief Operating Officer, President, and Member of the Board of Directors effective as of December 31, 2005. See note 15.

On February 2, 2005, the Company issued 20,000 options to a director. The options were issued with an exercise price of \$0.69 and with a term of 10 years. The options shall vest over three years, with 25% vesting on the date of the grant and 25% vesting on the anniversary of the grant date until fully vested. On December 11, 2005, the director had resigned from the Board, for personal reasons.

On April 11, 2005, the Company issued 50,000 options to a newly elected director. The options were issued with an exercise price of \$0.26 and with a term of 10 years. The options shall vest over three years, with 25% vesting on the date of the grant and 25% vesting on the anniversary of the grant date until fully vested.

On June 4, 2005, the Company issued 20,000 options to a director. The options were issued with an exercise price of \$0.28 and with a term of 10 years. The options shall vest over three years, with 25% vesting on the date of the grant and 25% vesting on the anniversary of the grant date until fully vested.

On August 19, 2005, the Company closed a private placement of securities from which they received gross proceeds of approximately \$2,000,000. The transaction consisted of the sale to one accredited investor, Blue Cedar Limited ("Blue Cedar"), of units consisting of: (i) 18,181,818 shares of common stock, (ii) warrants to purchase over a 5-year period 18,181,818 shares of common stock with an exercise price of \$0.165 and (iii) warrants to purchase over a 12-month period 12,121,212 shares of common stock with an exercise price of \$0.165. The Company relied upon the exemption from registration provided under Section 4(2) of the Securities Act of 1933, as amended (the "Securities Act") and Rule 506 of Regulation D promulgated thereunder. The private placement was only made available to one "accredited investor" as defined in Rule 501 of Regulation D and the required number of manually executed originals and true copies of Form D were and timely filed with the Securities and Exchange Commission. Lipworth Capital Limited acted as the placement agent in connection with the private placement. The Company paid an 8% fee to the placement agent and issued warrants to purchase 1,454,545 shares of common stock with an exercise price of \$0.165, in connection with the financing in addition to other costs. Additionally, the Company granted Blue Cedar certain registration rights pursuant to a registration rights agreement, dated as of August 17, 2005, in connection with this transaction. The registration rights agreement requires the Company to file

Edgar Filing: ASTRALIS LTD - Form 10KSB

a registration statement within approximately 30 days of the final closing of the Company's private placement covering the resale of all shares included therein, as well as the shares underlying the warrants. Because a registration statement covering the resale of such shares was not filed or effective by December 31, 2005, the date specified in the agreement, the Company is subject to a penalty of \$10,000 per month, being 0.5% of the aggregate purchase price, plus interest at 10% per annum.

F-26

Astralis, Ltd.
(A Development Stage Entity)
NOTES TO FINANCIAL STATEMENTS

NOTE 7 - CAPITAL STOCK ACTIVITY (Continued)

The Company evaluated its issuance of common stock and related warrants with Blue Cedar for possible application of derivative accounting under Statement of Financial Accounting Standard ("SFAS") No. 133: Accounting for Derivative Financial Instruments and Hedging Activities, Emerging Issues Task Force ("EITF") 00-19: Accounting for Derivative Financial Instrument Indexed to, and Potentially Settled in, A Company's Own Stock, EITF 01-6: The Meaning of "Indexed to a Company's Own Stock". It has determined that registration rights related to this issuance were subject to derivative accounting. In evaluating these registration rights and their related financial instruments the Company applied the methodology of View C in EITF 05-4 Issue Summary No. 1 and accounted for them as a freestanding instrument. The fair value of the registration rights agreements was determined to be minimal at September 30, 2005. However, at December 31, 2005, the Company determined the fair value to be \$83,000. The Company recognized this amount in expense and a corresponding liability in the accompanying financial statements.

In August 2005, the Board of Directors approved a resolution, subject to shareholder approval, to increase the authorized number of shares of common stock by 200,000,000 shares. The Company has not yet held a stockholders meeting to approve such amendment.

Preferred Stock

On December 13, 2001, the Company authorized 2,000,000 shares of preferred stock to be designated as "Series A Convertible Preferred Stock" ("Series A Preferred") with a \$0.001 par value per share. If the Company declares a dividend, holders of each share of Series A Preferred are entitled to non-cumulative cash dividends which will be the greater of i) 6% of the preferred share purchase price; or ii) the amount such holders would have received had the holders converted to common stock immediately prior to record date for payment of a dividend to holders of common stock. No dividend can be declared or paid on common stock without an equal or greater dividend being paid or declared on the Series A Preferred. Holders of each share of Series A Preferred were entitled to vote on all matters at stockholder meetings. Holders of each share of the Series A Preferred could convert their shares to common stock at an initial conversion price of \$2.50. The conversion price could be adjusted and reset as set forth in the purchase agreement for the Series A Preferred.

On December 10, 2001, the Company and SkyePharma entered into a purchase agreement whereby SkyePharma agreed to purchase 2,000,000 shares of Series A Preferred at a price of \$10 per share over a 13-month period with five separate closings. On December 10, 2002, the one-year anniversary of the agreement, SkyePharma received registration rights on the common stock underlying its

Edgar Filing: ASTRALIS LTD - Form 10KSB

Series A Preferred shares. The first closing occurred in December 2001 and the Company sold 1,000,000 shares of Series A Preferred for a purchase price of \$10,000,000.

The second, third and fourth closing occurred in January 2002, April 2002, and July 2002. On each closing, the Company sold 250,000 shares of Series A Preferred for a purchase price of \$2,500,000. The final 250,000 shares of Series A Preferred totaling \$2,500,000 closed on January 31, 2003.

The Company's stock price on December 10, 2001 was \$3.03; consequently, pursuant to the requirements of the Emerging Issues Task Force ("EITF") 98-5 "Accounting for Convertible Securities with Beneficial Conversion Features or Contingently Adjustable Conversion Ratios," as amended by EITF 00-27, the issuance of the Series A Preferred, which was convertible initially at \$2.50 per share at any time, resulted in a beneficial conversion feature recorded as a preferred stock dividend in the amount of \$2,120,000.

F-27

Astralis, Ltd.
(A Development Stage Entity)
NOTES TO FINANCIAL STATEMENTS

NOTE 7 - CAPITAL STOCK ACTIVITY (Continued)

The Company's stock price on April 30, 2002 was \$2.77; consequently, the issuance of the Series A Preferred, which was convertible initially at \$2.50 per share at any time, resulted in a beneficial conversion feature recorded as a preferred stock dividend in the amount of \$270,000.

Since the conversion price of the Series A Preferred was subject to reset provisions as described above, there was a beneficial conversion feature applicable to the Series A Preferred. Using the potential conversion price of \$1.60 for the first anniversary date as specified in the purchase agreement, the beneficial conversion feature resulted in an additional preferred stock dividend of \$9,078,750 in December 2002.

On January 20, 2004, Skyepharma converted all of its outstanding shares of Series A Preferred Stock of the Company into 25,000,000 shares of common stock at a reduced conversion price of \$0.80 per share. Skyepharma agreed that up to 12,500,000 shares of its common stock issued upon conversion of the Series A Preferred Stock will be subject to a call option at the discretion of the Company upon completion of an agreed upon milestone at a premium in excess of the conversion price. The call option can be exercised on or after July 21, 2004. Through the period ending on January 20, 2007, the exercise price will be between \$1.28 and \$1.52 per share. In connection with this transaction and in accordance with SFAS 84, "Induced Conversions of Convertible Debt, an Amendment of APB Opinion No. 26" the Company recorded a non-cash preferred stock dividend in January 2004 amounting to \$10,750,000.

Composition of Board

On the closing date of conversion, January 20, 2004, the Company and other original stockholders amended the stockholders agreement dated as of December 10, 2001. After the date of that Amendment, the Board of Directors is required to be comprised of at least seven directors and include at least two independent directors. Per the Amendment, Skyepharma shall have the right to nominate one director, who shall initially be Michael Ashton. From the date of the Amendment until the third anniversary, Jose Antonio O'Daly, Mike Ajnsztajn and Gaston Liebhaber (the "Founders"), each has the right to nominate one director. The

Edgar Filing: ASTRALIS LTD - Form 10KSB

Founders will initially be directors. The Agreement will terminate upon the later of (i) the SkyePharma Termination Date or (ii) the third anniversary of this Amendment, which is January 20, 2007. Further, this agreement may be terminated by the mutual written consent. "The SkyePharma Termination Date" is the date on which SkyePharma no longer beneficially owns, in the aggregate, at least 20% of the outstanding common stock of the Company.

Pursuant to the Blue Cedar Stockholder's Agreement, Blue Cedar may designate one director to the Company's Board of Directors. Manuel Tarabay is Blue Cedar's initial and current designated director. The Blue Cedar Stockholder's Amendment will terminate upon the later of the Blue Cedar Termination Date or August 15, 2008. The "Blue Cedar Termination Date" is the date on which Blue Cedar no longer beneficially owns, in the aggregate, at least 20% of the outstanding common stock of the Company.

F-28

Astralis, Ltd.
(A Development Stage Entity)
NOTES TO FINANCIAL STATEMENTS

NOTE 7 - CAPITAL STOCK ACTIVITY (Continued)

Stock Warrants

At December 31, 2005, the Company had the following outstanding common stock warrants to purchase its securities:

Number of Warrants Issued	Exercise Price Per Share
-----	-----
46,759,466	\$0.165 - \$4.00
=====	=====

These warrants were primarily issued in connection with the exchange with Astralis, LLC and the private placement offerings. These warrants expire between 2006 and 2010.

NOTE 8 - STOCK OPTION PLAN

On September 10, 2001, the Company adopted its 2001 Stock Option Plan that provides for the granting of options to officers, directors, employees, and consultants. The number of shares of common stock that can be purchased under this plan is limited to 5,000,000 shares, adjustable for changes in the capital structure of the Company. No options can be granted under this plan after September 10, 2011. Options granted under this plan may be either incentive stock options or non-qualified stock options. Options terms are not to exceed 10 years. The options have limited transferability, and will be subject to various vesting provisions as determined at the date of grant. The Board of Directors or a committee thereof will determine the exercise price of options granted in accordance with the provisions of this plan. The Board has the ability to amend, suspend or terminate this plan at any time, subject to restrictions imposed by applicable law.

On December 31, 2001, the Company granted two consultants options to purchase an aggregate 300,000 shares of the Company's common stock in exchange for their services. These options vest ratably, at 75,000 per year, over a four-year period commencing in 2001. The expiration terms of these options are 4 years, 3 years, 2 years and 1 year, for options vesting in 2001, 2002, 2003 and 2004,

Edgar Filing: ASTRALIS LTD - Form 10KSB

respectively. The strike price for all of these options is \$2.75.

During July 2002, the Company granted 15,000 stock options with a strike price of \$2.50, as compensation to a consultant.

The Company records deferred compensation when it makes compensatory stock option grants to employees, members of the Board of Directors, consultants or advisory board members. For the options granted to consultants, the amount of deferred compensation recorded is the fair value of the stock options on the grant date as determined using a Black-Scholes option-pricing model. The Company records deferred compensation as a reduction to shareholders' equity with an offsetting increase to additional paid-in capital. The Company then amortizes deferred compensation into stock-based compensation expense over the performance period, which typically coincides with the vesting period of the stock-based award.

During April 2003, the Company granted options to purchase 50,000 shares of common stock at an exercise price of \$0.45 per share to one of its directors. Options to purchase 12,500 shares of common stock vested on April 4, 2003, and options to purchase an additional 12,500 shares will vest each year thereafter for the following three years. In July 2004, 25,000 vested options were exercised.

F-29

Astralis, Ltd.
(A Development Stage Entity)
NOTES TO FINANCIAL STATEMENTS

NOTE 8 - STOCK OPTION PLAN (Continued)

On July 2, 2004, the Company granted options to purchase 50,000 shares of common stock at an exercise price of \$1.00 per share to one of its directors. Options to purchase 12,500 shares of common stock vested on grant date and options to purchase an additional 12,500 shares will vest each year thereafter for the following three years. The term of the options is four years.

During December 2004, the Company granted options to purchase 728,000 shares of common stock at an exercise price of \$0.70 per share to one of its officers. The options are vested immediately and expire in ten years.

In January 2005, the Company issued 100,000 shares of the Company's common stock along with 728,000 options to James Sharpe, the Company's former Chief Executive Officer and President. The options were issued with an exercise price of \$0.70 with a term of 10 years. The options vest over three years, with 25% vesting on the date of the grant and 25% vesting on the anniversary of the grant date until fully vested. Mr. Sharpe resigned as Chief Operating Officer, President, and Member of the Board of Directors as of January 25, 2006 with an effective resignation date of December 31, 2005. See Note 15.

On February 2, 2005, the Company issued 20,000 options to a director. The options were issued with an exercise price of \$0.69 and with a term of 10 years. The options shall vest over three years, with 25% vesting on the date of the grant and 25% vesting on the anniversary of the grant date until fully vested.

On April 11, 2005, the Company issued 50,000 options to a newly elected director. The options were issued with an exercise price of \$0.26 and with a term of 10 years. The options shall vest over three years, with 25% vesting on the date of the grant and 25% vesting on the anniversary of the grant date until fully vested.

Edgar Filing: ASTRALIS LTD - Form 10KSB

On June 4, 2005, the Company issued 20,000 options to a director. The options were issued with an exercise price of \$0.28 and with a term of 10 years. The options shall vest over three years, with 25% vesting on the date of the grant and 25% vesting on the anniversary of the grant date until fully vested.

NOTE 9 - DEFERRED COMPENSATION

The components of deferred compensation for the options granted are as follows at December 31,

	2005	2004
	-----	-----
Balance at January 1	\$ --	\$ 4,822
Deferred compensation recorded	65,000	--
Fair value adjustments	--	--
Amortization to stock-based compensation	(65,000)	(4,822)
	-----	-----
Balance at December 31	\$ -- =====	\$ -- =====

F-30

Astralis, Ltd.
(A Development Stage Entity)
NOTES TO FINANCIAL STATEMENTS

NOTE 9 - DEFERRED COMPENSATION (Continued)

Exercise prices for stock options outstanding as of December 31, 2005 and the weighted average remaining contractual life are as follows:

Exercise Prices	Options Outstanding	Weighted Average Remaining Contractual Life	Number Exercisable
-----	-----	-----	-----
\$ 0.26 - 0.28	70,000	9.32 years	17,500
\$ 0.45	25,000	2.26 years	12,500
\$ 0.69 - 0.70	1,294,000	9.03 years	915,000
\$ 1.10	50,000	8.43 years	25,000
\$ 2.50	15,000	1.69 years	15,000

In accordance with FAS 123 the fair value of the options were estimated as of the date of the grant or subsequent vesting date, or December 31, 2005 if not vested, using a Black-Scholes option-pricing model. The assumptions used in estimating the fair value of the options ranged as follows:

Volatility	100% - 130%
Risk-free interest rate	2.3% - 4.78%
Expected life	5 - 10 years
Dividend yield	--

The Company had the following outstanding common stock options to purchase its securities at December 31:

Edgar Filing: ASTRALIS LTD - Form 10KSB

Description of Series	2005		2004
	Number of Options issued	Exercise Price Per Share	Number of Options issued
Expire December 2005	--	\$ --	300,000
Expire September 2007	15,000	\$ 2.50	15,000
Expire April 2008	25,000	\$ 0.45	--
Expire June 2014	50,000	\$ 1.10	--
Expire December 2014	728,000	\$ 0.70	803,000
Expire February 2015	20,000	\$ 0.69	--
Expire February 2015	546,000	\$ 0.70	--
Expire April 2015	50,000	\$ 0.26	--
Expire June 2015	20,000	\$ 0.28	--
Common Stock	1,454,000		1,118,000

F-31

Astralis, Ltd.
(A Development Stage Entity)
NOTES TO FINANCIAL STATEMENTS

NOTE 9 - DEFERRED COMPENSATION (Continued)

The following tables summarize the Company's stock option activity and related information:

	Number of Shares
Balance as of December 31, 2003	365,000
Granted	778,000
Exercised	(25,000)
Expired/forfeit	--
Balance as of December 31, 2004	1,118,000
Granted	818,000
Exercised	--
Expired/forfeit	(482,000)
Balance as of December 31, 2005	1,454,000

NOTE 10 - RELATED PARTY - TRANSACTIONS/COMMITMENTS/INDEMNIFICATIONS

Patent

A founding member of the Company is the owner of a patent application, filed March 16, 2001 with the United States Patent and Trademark Office, entitled "Compositions and Methods for the Treatment and Clinical Remission of Psoriasis"

Edgar Filing: ASTRALIS LTD - Form 10KSB

(the "Invention"). On April 26, 2001, the Company, in exchange for \$10, entered into an exclusive license agreement to use and exploit the Invention, the technology related thereto, and the related patent rights, including the ability to license foreign patent rights. The term of the license agreement expires on the last date of expiration of the patent or earlier date as specified in the license agreement.

During the term of the license agreement, the Company is required to pay all fees and costs relating to the filing, prosecution, and maintenance of the patent and associated rights. In addition, the Company is required to pay all reasonable attorneys' fees of the Company, or patent owner, in the pursuit of any patent infringement litigation.

The recorded value of the patent was impaired as of December 31, 2005 and the Company recorded an impairment charge of \$114,976 in relation to the patent (see Note 4)

SkyePharma PLC Agreements

On December 10, 2001, the Company executed three agreements with SkyePharma, a pharmaceutical company located in England.

The Company entered into a stock purchase agreement whereby SkyePharma agreed to purchase 2,000,000 shares of Series A Preferred at a price of \$10 per share in five separate closings over a 13-month period commencing in December 2001 (see Note 7).

F-32

Astralis, Ltd.
(A Development Stage Entity)
NOTES TO FINANCIAL STATEMENTS

NOTE 10 - RELATED PARTY - TRANSACTIONS/COMMITMENTS/INDEMNIFICATIONS (Continued)

The Company entered into a technology option agreement whereby it agreed to pay SkyePharma \$5,000,000 in return for the right, for 7 years, to enter into a non-exclusive license agreement with SkyePharma to utilize three drug delivery systems (\$2,000,000, \$2,000,000, and \$1,000,000, respectively per delivery system). The royalty fee in this license agreement is specified to be 5% of the net sales of any product the Company sells utilizing a SkyePharma drug delivery system. All other terms of this license agreement would need to be determined upon exercise of the option. The Company can transfer this option to another party, subject to approval by SkyePharma. This license would only allow the Company to use these delivery systems for drugs that treat two particular immunotherapies - psoriasis and leishmaniasis. The \$5,000,000 fee was required to be paid on December 10, 2001 and was netted (for convenience purposes) out of the first \$10,000,000 installment purchase of preferred stock by SkyePharma.

The technology option was impaired as of December 31, 2004 and the Company recorded an impairment charge of \$2,797,612 in relation to the option (see Note 7).

The Company entered into a services agreement whereby it paid \$11,000,000 to SkyePharma in return for SkyePharma providing all development, manufacturing, pre-clinical and clinical development services for the Company's primary - second generation Psoraxine, up to the completion of Phase II clinical studies. The contract recognized that SkyePharma performed \$3,000,000 of these services in the fourth quarter of 2001 and that SkyePharma will perform and be paid for the remaining \$8,000,000 of services in 2002 and 2003. The payment terms for the

Edgar Filing: ASTRALIS LTD - Form 10KSB

services agreement are fixed. The Company paid \$3,000,000 in 2001, \$7,980,000 in 2002 and \$20,000 in 2003.

The service agreement was terminated on December 31, 2002. In March 2003, the Company and SkyePharma amended the original service agreement, effective January 1, 2003, to extend the term of the agreement and modify the services to be provided by SkyePharma. SkyePharma will continue to provide certain services to the Company through December 31, 2004 in consideration for payments it received from the Company during 2002 in connection with this agreement, as a prepaid expense. This prepaid amount will be expensed during the remaining period of the amended service agreement. In 2004, the Company expensed \$1,007,500 in connection with the services agreement.

SkyePharma has the right of first negotiation to acquire the worldwide licensing and distribution rights to Psoraxine up to the completion of the Phase II studies. On completion of Phase II studies, Astralis will offer SkyePharma the option to acquire the worldwide licensing and distribution rights to Psoraxine. If SkyePharma does not take the option, Astralis will seek a marketing partner to fund Phase III clinical studies and to provide a sales and marketing infrastructure.

As of December 31, 2005, SkyePharma owns approximately 39.8% of the Company's outstanding common stock.

Indemnification

The Company has agreed, subject to specific provisions in the Technology Access Agreement, to indemnify SkyePharma, its directors and employees against any and all losses, claims, demands, proceedings, actions, etc. which may be brought or established against them as a result of, among other items, i) negligence of Company personnel or contractors or ii) death, personal injury or property damage or loss caused by the Company selling a product containing a SkyePharma delivery system which is defective or not merchantable. However, this indemnification does not apply to any death or personal injury arising from defects inherent in the delivery systems or technical know-how of SkyePharma licenses with the delivery system technology.

F-33

Astralis, Ltd.
(A Development Stage Entity)
NOTES TO FINANCIAL STATEMENTS

NOTE 11 - OPERATING LEASES

On March 13, 2002, the Company entered into a lease agreement for laboratory and office space. The lease period is for three years and rent is \$77,500 annually. The Company also entered into a concurrent service agreement with the lessor of the laboratory space on a time and material basis. During 2005, the Company extended its lease through September 2006 for \$110,400 annually.

During 2005 and 2004, the Company leased two apartments and an automobile for two different key employees, one of whom is an officer. During 2005, the Company canceled its obligation under these leases and carried no other leases for key employees.

The Company incurred rent expense in the amount of \$98,642 and \$128,443 for 2005 and 2004, respectively.

The following is a schedule by year of future minimum rental payments required

Edgar Filing: ASTRALIS LTD - Form 10KSB

under operating leases, as of December 31, 2005:

Year Ending December 31:	
2006	\$ 82,800
Thereafter	--

NOTE 12 - COMPREHENSIVE LOSS

Excluding net loss, the Company's source of comprehensive loss is from the net unrealized loss on its marketable debt securities, which are classified as available-for-sale. The following summarizes the components of comprehensive loss:

	Year Ended December 31,	
	2005	2004
Net loss	\$ (3,914,159)	\$ (20,037,568)
Unrealized gain (loss) on securities:		
Unrealized gain arising during period	--	--
Reclassification adjustment for loss realized in net loss	--	27,698
Unrealized gain (loss), net	--	27,698
Comprehensive loss	\$ (3,914,159)	\$ (20,009,870)

NOTE 13 - CONCENTRATIONS

The Company currently has two products that are under development. Lack of product development or customer interest could have a materially adverse effect on the Company. Further, significant changes in technology could lead to new products or services that compete with the product to be offered by the Company. These changes could materially affect the price of the Company's products or render them obsolete.

F-34

Astralis, Ltd.
(A Development Stage Entity)
NOTES TO FINANCIAL STATEMENTS

NOTE 14 - SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION

The Company paid \$2,307 and \$0 in interest for 2005 and 2004, respectively. The Company did not pay any taxes in 2005 or 2004.

In April 2005, the Company financed \$24,184 of its business liability insurance premiums by entering into a short-term note payable. The note matures on February 16, 2006 and bears interest at a rate of 6.75% per annum. As of December 31, 2005, this note had an outstanding balance of \$4,946.

Edgar Filing: ASTRALIS LTD - Form 10KSB

In January 2005, the Company financed \$33,516 of its directors and officers liability insurance premiums by entering into a short-term note payable. The note matured on November 10, 2005 and bears interest at a rate of 5.75% per annum. As of December 31, 2005, this note had an outstanding balance of \$0.

In December 2004, the Company financed \$28,280 of its directors and officers liability insurance premiums by entering into a short-term note payable. The note matures on October 10, 2005 and bears interest at a rate of 6.65% per annum. As of December 31, 2005 and 2004, this note had an outstanding balance of \$0 and \$28,280, respectively.

NOTE 15 - SUBSEQUENT EVENTS

On March 31, 2006, the Company issued to Blue Cedar Limited ("Blue Cedar"), an accredited investor and currently a stockholder of the Company; (i) a convertible promissory note in the principal amount of \$250,000, convertible into shares of the Company's common stock at \$0.09 per share at any time prior to the redemption date (March 31, 2009), interest will be charged on the note at 6% per annum and (ii) a warrant to purchase 2,777,778 shares of common stock at an exercise price of \$0.135 per share. The warrants expire five years from the date of issuance.

On January 25, 2006, the Company's Chief Executive Officer and President, James Sharpe, resigned pursuant to a Separation Agreement and General Release ("Separation Agreement"), by and between the Company and Mr. Sharpe. The resignation was effective as of December 31, 2005. The separation agreement calls for the following:

- \$50,000 severance payment payable within 10 days of the signing of the separation agreement;
- All non-vested stock options have been terminated;
- The Company shall grant to Mr. Sharpe, an option to purchase 182,000 shares of common stock on January 27, 2006 at the market price on that date;
- The Company shall grant to Mr. Sharpe, an additional option to purchase 182,000 shares of common stock on January 27, 2007 at the market price on that date;
- The Company will pay for Mr. Sharpe's COBRA premiums for six months after the separation date or until the date he becomes eligible for employer-provided benefits from another employer, whichever occurs first.

At December 31, 2005, the company has accrued the severance payment of \$50,000 in the accompanying financial statements. The unvested options granted to Jim Sharpe in 2005 that were previously expensed under FASB 148 disclosure have been reversed in footnote 2. The new options granted with the separation agreement will be accounted for under FASB 123(R) in 2006.